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ABSTRACT 
Werner syndrome (WS) is an autosomal recessive disorder associated with 
premature aging and cancer predisposition. WS cells show increased genomic instability 
and are hypersensitive to DNA-damaging agents. WS is caused by mutations of the WRN 
gene. WRN protein is a member of RecQ DNA helicase family. In addition to a 
conserved 3’–5’ helicase activity, the WRN protein contains unique 3’–5’ exonuclease 
activity. WRN recognizes specific DNA structures as substrates that are intermediates of 
DNA metabolism. WRN physically and functionally interacts with many other proteins 
that function in telomere maintenance, DNA replication, and DNA repair.  The function 
of WRN is regulated by post–translational modifications that include phosphorylation, 
acetylation, and sumoylation.  
SIRT1 is a NAD-dependent histone deacetylase (HDAC) that deacetylates 
histones and a numbers of cellular proteins. SIRT1 regulates the functions of many 
proteins, which are important for apoptosis, cell proliferation, cellular metabolism, and 
DNA repair. SIRT1 is also regulated by other proteins or molecules from different levels 
to activate or inhibit its deacetylase activity.  
In this study, we found that SIRT1 interacts with and deacetylates WRN. We 
further identified the major acetylation sites at six lysine residues of the WRN protein and 
made a WRN acetylation mutant for functional analysis. We found that WRN acetylation 
increases its protein stability. Deacetylation of WRN by SIRT1 reverses this effect. 
CREB-binding protein (CBP) dramatically increased the half-life of wild-type WRN, 
while this increase was abrogated with the WRN acetylation mutant. We further found 
xvi 
 
that WRN stability is regulated by the ubiquitination pathway, and that WRN acetylation 
by CBP dramatically reduces its ubiquitination level.  
We also found that acetylation of WRN decreases its helicase and exonuclease 
activities, and that SIRT1 reverses this effect.  Acetylation of WRN alters its nuclear 
distribution. Down-regulation of SIRT1 increases WRN acetylation level and prevents 
WRN protein translocating back to nucleolus after DNA damage. Importantly, we found 
that WRN protein is strongly acetylated and stabilized in response to mitomycin C 
(MMC) treatment. H1299 cells that were stably expressing WRN acetylation mutant 
display significantly higher sensitivity to MMC than the cells expressing wild-type WRN. 
Taken together, these data demonstrated that acetylation pathway plays an important role 
in regulating WRN function in response to DNA damage. A model has been proposed 
based on our discoveries.  
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CHAPTER 1: Introduction 
1.1 Werner syndrome and its cellular phenotype 
Werner syndrome (WS) is a human autosomal recessive disorder. Due to its 
symptoms, WS is also considered an adult-onset segmental progeroid syndrome. WS 
patients grow normally until their adolescent stage of  life, when numerous age-related 
disorders, (e.g. short stature, skin atrophy, graying and loss of hair, bilateral cataracts, 
type II diabetes mellitus, osteoporosis, hypogonadism, soft tissue calcification, and 
cancer), begin to display. These patients have an elevated incidence of cancer, especially 
early onset of mesenchymal tumors such as soft tissue and bone sarcomas. The average 
age of WS patients is 54 years, and they die mostly of cancer or vascular disease. [1]  
Cultured cells from WS patients have reduced life spans. They undergo premature 
replicative senescence much faster than normal cells do  [2].  WS cells are extremely 
sensitive to several DNA-damaging drugs, including 4-Nitroquinoline 1-oxide (4NQO) 
[3], to topoisomerase inhibitors such as camptothecin (CPT) [4], and to DNA cross-
linking drugs like MMC, melphalan, chlorambucil [5].  WS cells show increased 
genomic instability, such as chromosomal rearrangements, translocations, inversions, and 
extensive deletions [6]. Moreover, WS cells undergo prolonged S phase in cell cycle [7]. 
These WS cellular phenotypes indicate that the protein responsible for this syndrome is 
related to DNA metabolism, including telomere maintenance, DNA repair, DNA 
recombination and DNA replication. 
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1.2 WRN protein and the RecQ helicase family 
WS is caused by mutations of the WRN gene, a member of the RecQ helicase 
family [8], which includes four other members, including RECQ1, BLM,  RECQ4, and 
RECQ5 [9]. BLM mutation causes Bloom syndrome (BS) [10], and mutations of RECQ4 
cause Rothmund Thomson syndrome (RTS), RAPADILINO syndrome, and Baller 
Gerold syndrome (BGS) [11]. Compared to the five members in human, there is only one 
RecQ homolog in E. coli (named RecQ), and yeast (named Sgs1 in S. cerevisiae and 
Rqh1 in S. pombe) [9].  
There are three conserved regions in the proteins of this family (Figure 1.1): the 
helicase domain, the RecQ carboxyl-terminal (RQC) domain and the Helicase and RNase 
D C-terminal (HRDC) domain. The helicase domain comprises about 400 residues, 
including seven sequence motifs. This domain is responsible for ATP hydrolysis, 
providing the energy for the complementary strands to be separated. The RQC domain is 
the unique domain for the RecQ family members that play important roles in protein-
protein and protein-DNA interactions [12] [13]. The function of  the HRDC domain is 
suspected of helping RecQ proteins bind to DNA [14] [15].  
WRN is a protein of 1432 amino acid residues. Like other members of the human 
helicase RecQ family, it contains 3’–5’ helicase activity and DNA-dependent ATPase 
activity. Uniquely, the WRN N-terminus contains an DnaQ-like exonuclease domain with 
3’–5’ exonuclease activity [16]. The exonuclease domain is also found in WRN 
orthologue FFA-1 in Xenopus laevis. WRN also has single-strand DNA annealing 
activity, which seems to be contrary to its helicase activity. Machwe et al. reported that 
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WRN combined its strand pairing and unwinding activities to perform coordinated strand 
exchange [17]. They also demonstrated that WRN can coordinate these two activities to 
regress a model replication fork substrate [18]. 
WRN contains, at its C-terminus, a nuclear localization signal (NLS) that is 
responsible for its import into the nucleus after translation. Additionally, there is a 
nucleolar-targeting sequence (NTS) within residues 949–1092 in the WRN protein [19]. 
In normal conditions, most of the WRN protein localizes in nucleoli, where ribosomal 
RNA is transcribed and assembled, yet the function of WRN in nucleoli is not clear.  
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Figure 1.1 The RecQ helicase family. Human RecQ helicase family has five members, 
including RECQ1, BLM, WRN, RECQ4, and RECQ5. There is only one RecQ homolog 
in E. coli (RecQ), S. cerevisiae (Sgs1) and S. pombe (Rqh1). The helicase domain, the 
RecQ carboxyl-terminal (RQC) domain and the Helicase and RNase D C-terminal 
(HRDC) domain are as indicated. WRN contains an additional exonuclease (Exo) domain 
within the N-terminal region. RECQ4 contains the Sld2-like domain as indicated. The 
size of each protein is shown on the right. Adapted from Chu and Hickson [9]. 
  
(Chu and Hickson, Nature Review, 2009) 
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1.3 WRN enzymatic activities and substrates 
As mentioned above, WRN bears intrinsic 3’–5’ helicase activity and 3’–5’ 
exonuclease activity with specific substrates for these two activities. For helicase activity, 
WRN unwinds 3’-ss DNA tail duplexes, but not duplexes with blunt ends or 5’-ss DNA 
tails [20]. The 3’-ss DNA tails exist in the form of D-loops of telomeres [21], and in the 
first step of DNA double-strand break repair though HR [22]. Other than 3’-ss DNA tail 
duplexes, WRN prefers to unwind several substrates, which are intermediates in DNA 
metabolism, including DNA replication, recombination, transcription, repair, and 
telomere maintenance. These substrates include forks, bubbles and flaps, (which are 
intermediates in DNA replication, transcription and repair); Holliday junctions (HJ), D-
loops, 3-way junctions, (which are intermediates in DNA recombination); triple helix, G-
quadruplex DNA (which are associated with telomeric DNA) (reviewed in [23]).  
For exonuclease activity, WRN digests 5’-overhang duplexes from the 3’-
recessed terminal, but not duplexes with blunt ends or 3’-ssDNA tails [24]. It also 
degrades a duplex blunt end substrate with junction or alternate structures, such as 
bubbles, forks, and HJ [25], which are also substrates for WRN helicase activity. This 
suggests that WRN helicase and exonuclease activities coordinate in some processes. 
Opresko et al. demonstrated that on a model telomeric D-loop, the WRN helicase and 
exonuclease acted simultaneously to release the 3’-invading tail [21], which will be 
discussed in detail later.  
In summary, the substrate specialty of WRN enzymatic activities indicates that 
WRN protein plays an important role in DNA metabolism, using its helicase and/or 
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exonuclease activity, and these two enzymatic activities coordinate with each other in the 
processes.   
1.4 WRN knockout mouse  
WS patients display premature age symptoms, which makes it a good model 
system to study aging. Three research groups have established WRN knockout mouse 
models using different strategies and got very different results. Lebel and Leder targeted 
the exons that encode motifs III and IV of the helicase domain in mouse WRN protein, 
resulting in fully translated WRN protein without helicase activity, designated as WRN 
Δhel/ Δhel. The WRN Δhel/ Δhel mice appeared normal during their first year of life. Several 
DNA repair systems were intact in WS cells from the mice, although WS cells are more 
sensitive to topoisomerase inhibitors and have reduced proliferation activity [26]. 
Lombard et al. targeted the last exon of the helicase domain, which resulted in the 
expression of a truncated protein, a situation similar to that seen in many human WS 
patients. This mouse model is considered as WRN-/-. The WRN-/- mice were perfectly 
healthy. WRN-deficient cells were not hypersensitive to 4NQO or CPT. The life span of 
these cells did not decrease. However, the p53-/-WRN-/- double-knockout mice died 
earlier [27]. 
The results from both models were disappointing. Neither of them developed WS-
like phenotypes as expected. One explanation of this discrepancy is that the telomeres of 
mice are much longer than those of humans. WRN protein plays an important role in 
telomere maintenance, which will be discussed in more detail later. Therefore, the length 
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of telomeres of mice might effectively mask the effect of a loss of WRN protein function. 
Indeed, this hypothesis has been demonstrated by a third mouse model. Chang et al. 
knocked out both WRN and Terc in mice. The Terc gene encodes the telomerase RNA 
component. The double knockout mice displayed WS-like phenotypes, such as premature 
death, hair graying, alopecia, osteoporosis, type II diabetes and cataracts. The cells from 
these mice showed accelerated replicative senescence and accumulation of DNA damage 
foci. These knockout mice also showed increased genomic instability and higher 
incidence of cancers, especially nonepithelial malignancies. The late generation of the 
double knockout mice displayed classic features of WS patients, which makes it a good 
model to further study human WS [28]. 
1.5 WRN functions in telomeres 
Only the WRN-/- Terc-/- mouse model displays phenotypes similar to WS patients, 
indicating that WRN plays an important role in telomere maintenance, and telomere 
dysfunction is the major reason for the phenotypes of WS. Telomeres are structures that 
cap and protect the ends of eukaryotic chromosomes [29]. Telomeres consist of 
TTAGGG repetitive sequences with a 3’ single strand G-rich overhang, and the 3’ 
overhang invades a duplex region of the telomere to sequester the overhang, forming a D 
loop structure. G-quadruplexes and D-loops are preferred substrates for WRN helicase 
and exonuclease activities. Telomeres will become shorter and shorter along with cell 
division, and eventually the cells will stop dividing, thus undergoing replicative 
senescence [30]. The direct evidence that WRN functions in telomere maintenance has 
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been provided by Crabbe et al. They found that the replication of telomeres by lagging 
strand synthesis is compromised in WRN-deficient cells, and WRN helicase activity is 
required for the replication of telomere lagging strand. WRN may use its helicase activity 
to resolve aberrant DNA structures such as G-quadruplex formation on the lagging G-rich 
telomeric DNA during telomere replication [31]. 
WRN physically and functionally interacts with TRF1 (Telomere Repeat-Binding 
Factor 1), TRF2 (Telomere Repeat-Binding Factor 2) and POT1 (Protection of telomeres 
protein 1) [24, 32–34]. These proteins are members of the telosome/shelterin complex, 
which specially binds to and stabilizes the telomeric D-loop [30]. WRN co-localizes with 
TRF1 and TRF2 at telomeric DNA in human ALT (alternative lengthening of telomeres) 
cell lines [21]. TRF2 directly interacts with WRN’s C-terminal region (AA 949–1092), 
and recruits WRN to telomeric substrates [32] [33]. TRF2 stimulates WRN helicase 
activity to resolve telomeric D-loops in vitro [32], while TRF1 and TRF2 inhibit WRN 
exonuclease activity [21]. WRN helicase and exonuclease activities act simultaneously 
and cooperate to release an intact 3’ tail. Conversely, Machwe et al. reported that TRF2 
facilitates WRN exonuclease activity on telomeric substrates [33], and they explained the 
discrepancies by different reaction conditions.  POT1, the telomeric single strand DNA 
binding protein, also interacts with WRN, and stimulates WRN helicase activity to 
release an intact telomeric tail from a D-loop structure [34]. In this scenario, WRN may, 
during telomere replication and/or recombination, facilitate unwinding of the D-loops to 
release the 3’ invading tails along with its partners such as TRF1, TRF2 and POT1.  
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In addition, WRN may play a role in repressing aberrant telomere sister chromatid 
exchange (T-SCE). The T-SCEs are elevated in later generations of mTerc-/- Wrn-/- cells, 
and the restoration of wild-type WRN to this cell line decreases T-SCE levels [35].  
In summary, WRN functions in telomere maintenance through resolving the G-
quadruplexes and D-loop during telomere replication, and repressing aberrant homolog 
recombination (HR) between telomeres of sister chromatids. These functions of WRN in 
telomere maintenance might help us to understand why WS patients show premature 
aging symptoms and why WS cells undergo premature replicative senescence and display 
increased genomic instability.  
1.6 WRN functions in DNA replication 
As mentioned above, WS cells undergo premature replicative senescence, 
displaying an extended S-phase in cell cycle. Moreover, WS cells have a reduced 
frequency of replication initiation sites [36]. DNA replication intermediates, such as forks 
and flaps, are specific substrates for WRN enzymatic activities. WRN also plays a role in 
telomere replication. The Xenopus orthologue of WRN, FFA-1, is required for DNA 
replication [37]. In addition, WRN physically and functionally interacts with many 
proteins that function in DNA replication, including RPA (replication protein A), FEN-1 
(Flap endonuclease 1), DNA polymerase δ (pol δ), PCNA (proliferating cell nuclear 
antigen), and Topo I (topoisomerase I) [38–45]. 
Brosh et al. reported the first WRN interacting protein: RPA, which is an 
important single-strand DNA-binding protein in DNA replication. RPA can stimulate 
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WRN helicase activity to unwind long duplex DNA substrates up to 849 bases [38]. After 
hydroxyurea (HU) treatment, which causes replication fork arrest, WRN co-localizes 
with RPA in nuclear foci [39]. This finding suggests that WRN may function in restoring 
stalled replication forks.   
FEN-1 processes the 5' ends of Okazaki fragments in lagging-strand DNA 
synthesis. WRN interacts with FEN-1 through WRN’s C-terminal region (AA 949–1432), 
and dramatically stimulates FEN-1 activity to cleave a 5'-flap-DNA substrate [40]. This 
interaction implies that WRN functions in lagging-strand DNA synthesis.  A later report 
that WRN is required for telomere lagging-strand synthesis supports this view [31].  
WRN also interacts with DNA pol δ. Pol δ is the major DNA polymerase in DNA 
replication. The WRN C-terminus directly interacts with the p50 subunit of pol δ. Ectopic 
expression of WRN recruits both p50 and p125 (the catalytic subunit) to the nucleolus 
[41]. This study suggests that WRN may regulate DNA replication by recruiting pol δ to 
sites of DNA synthesis, such as nucleolus where rDNA is replicated. Kamath-Loeb et al. 
reported that WRN increases the rate of nucleotide incorporation by pol δ in the absence 
of PCNA [42]. They also found that WRN helps pol δ to traverse the structures that can 
effectively impede DNA synthesis, such as hairpins and G'2 bimolecular tetraplex of the 
fragile X expanded sequence, d (CGG) (n), which are specific substrates for WRN 
helicase activity [43]. WRN interacts with other two important components of the DNA 
replication complex: PCNA and Topo I.  PCNA binds to the WRN N-terminal region 
(AA 168–246) [44], and WRN and PCNA co-localize in DNA replication sites [45]. 
Topo I interacts with the WRN N-terminal (AA 1–51) and C-terminal regions (AA 949–
11 
 
1432). WRN stimulates Topo I DNA relaxation activity, while Topo I inhibits the 
helicase and ATPase activities of WRN [46]. 
The above findings demonstrate that WRN functions in DNA replication, 
although the precise role of WRN is still not clear. One possible role of WRN in DNA 
replication is to act as a “roadblock remover”, eliminating the abnormal DNA structures 
to ensure that replication continues. Another possible role of WRN is to help the restart of 
stalled replication forks. In this model, a lesion in the leading strand causes stalling of 
leading-strand synthesis, while the lagging strand continues to replicate. The replication 
fork regresses and forms a partially single-stranded “chicken foot." Then the leading 
strand uses the lagging strand as a template to synthesize DNA, forming a four-way 
junction. The replication fork resets by branch migration of the four-way junction, maybe 
through WRN and/or BLM. Finally, the replication fork is restored, and the leading 
strand is extended beyond the lesion.  
1.7  WRN functions in DNA double strand break (DSB) repair 
A DSB is one of the most dangerous types of DNA damage that occurs in 
mammalian cells. DSBs are caused by ionizing radiation (IR), oxidative free radicals, 
replication across a nick, or topoisomerase failure [47]. Defects in DSB repair cause 
genomic instability, cancer predisposition, and premature aging. Two pathways are used 
to repair DSBs: homologous recombination (HR) and non-homologous end-joining 
(NHEJ).  
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As discussed above, WS cells are hypersensitive to numerous DNA-damaging 
drugs, including DSB inducers such as CPT. WRN accumulates rapidly at the sites of 
DSBs induced by laser micro-irradiation in a time-dependent manner, and this 
accumulation is independent of DNA replication and other interacting proteins [48]. 
WRN may function in DNA DSB repair through both HR and NHEJ pathways, and this 
idea has been supported by the fact that WRN physically and functionally interacts with 
many proteins that are important for these two pathways. But the specific role of WRN in 
DNA DSB repair remains obscure.     
1.7.1 WRN functions in DNA DSB repair through the HR pathway 
HR is an error-free homology-directed repair pathway. A DSB is repaired by 
using the undamaged sister chromatid as a template to repair the broken sister chromatid. 
HR consists of three stages: (1) formation of a nucleoprotein filament, (2) strand invasion, 
(3) branch migration and Holliday junction (HJ) resolution [22] [49]. 
WRN physically and functionally interacts with many proteins involved in the HR 
pathway, including the MRN complex (Mre11, Rad50, and Nbs1), BRCA1, RPA, 
RAD51, RAD52, and BLM [50–56]. The MRN complex functions as a DSB sensor and, 
in the first step of HR, processes the damaged DNA ends to generate the 3’ overhang tail 
with its exonuclease activity. Nbs1 interacts with WRN exonuclease and helicase 
domains, and the association between WRN and the MRN complex is increased in 
response to DNA damage. WRN co-localizes with Nbs1 in response to IR and MMC 
treatment. The MRN complex stimulates WRN helicase activity, without altering WRN 
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exonuclease activity [50]. BRCA1 inhibits the nuclease activity of the MRN complexes 
to limit extensive digestion [51]. WRN interacts directly with BRCA1, and this 
interaction is increased after DNA damage, such as the damage caused by psoralen (a 
drug that induces DNA interstrand crosslinks) and IR treatment. Although BRCA1 
stimulates WRN helicase and exonuclease activities, processing of DNA interstrand 
crosslinks (ICLs) requires only the helicase, but not the exonuclease activity [52]. RPA 
binds to the 3’ single-stranded DNA tails generated by MRN complexes, and it stimulates 
the assembly of Rad51 to the single-stranded region. RPA also interacts with WRN and 
stimulates WRN helicase activity [38]. Rad51 is an important strand exchange protein for 
HR, and Rad51 polymerizes on the 3’ tail to create a nucleoprotein filament. Although a 
direct WRN-Rad51 interaction has not been reported, WRN co-localizes with RAD51 in 
discrete nucleoplasmic foci after DNA-damage treatment [53-54]. Rad52 is required for 
Rad51 recruitment and RPA displacement. Rad52 interacts with the WRN C-terminal 
region (AA 982–1432). Rad52 both inhibits and enhances WRN helicase activity in a 
DNA structure dependent manner, while WRN increases Rad52 strand annealing activity 
[55]. BLM is also a member of the RecQ helicase family, and it resolves the HJ (Holliday 
junction) formed in the HR process [56]. BLM directly binds to the N-terminal and RQC 
containing domains of WRN. BLM specifically inhibits the exonuclease activity of WRN 
[57].  
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1.7.2 WRN functions in DNA DSB repair through the NHEJ (non-homologous 
end-joining) pathway 
NHEJ is the simplest way to repair a DSB. This DSB repair pathway directly 
rejoins the two severed DNA ends in a sequence independent fashion. Many proteins are 
required to efficiently perform NHEJ. The Ku complex (Ku70/Ku80) binds to DNA ends. 
This DNA–Ku complex then attracts and activates the catalytic subunit of DNA-
dependent protein kinase (DNA-PKCS), a serine/threonine protein kinase, to form DNA-
PK complex. DNA-PK then attracts the ligase IV complex (comprised of ligase IV, 
XRCC4 and XLF), which together seal the DNA ends. The MRN complex may facilitate 
tethering of the two DNA ends [58].  
WRN physically and functionally interacts with many proteins that function in the 
NHEJ pathway, including Ku complex, DNA-PKcs, and XRCC4-DNA ligase IV 
complex (X4L4). Three different groups have reported a physical interaction between 
WRN and Ku complex [59] [60] [61]. The Ku70 subunit interacts with the WRN N-
terminal region (AA 1–368), and the Ku80 subunit interacts with its C-terminal region 
(AA 940–1432) [60]. However, Cooper et al. reported that both Ku70 and Ku80 interact 
with the WRN C-terminal region (AA 940–1432) [59], whereas Li et al. demonstrated 
that the Ku complex interacts with WRN N-terminal region (AA 1–50) [61]. WRN can 
form a stable complex on DNA in the presence of the Ku complex, suggesting that the 
Ku complex recruits WRN to DNA ends through specific protein-protein interaction [61]. 
WRN and the Ku complex co-localize in a subset of nuclear foci, particularly after 
treatment with 4NQO (a UV-mimetic agent), suggesting that the WRN-Ku complex 
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interaction may be important for processing of DNA damage induced by 4NQO [62]. The 
Ku complex has no effect on WRN helicase activity, but stimulates its exonuclease 
activity [59]. This stimulation is dependent on the presence of both Ku70 and Ku80 [61]. 
The exonuclease activity of WRN is severely inhibited in the strand of the DNA of 
certain modified nucleotides, such as 8-oxoG, 8-oxoA. The Ku complex permits the 
WRN exonuclease to digest through regions containing either 8-oxoG or 8-oxoA [62].  
Two groups, with different results, reported WRN and DNA-PK complex 
interactions [63-64]. Yannone et al. reported that WRN interacts with DNA-PKcs directly 
and independently of the Ku complex; DNA-PKcs inhibits both helicase and exonuclease 
activities of WRN in a phosphorylation-independent manner and Ku relieves this 
inhibition [63]. The other group demonstrated that the Ku complex mediates WRN and 
DNA-PKcs interactions and that DNA-PKcs inhibits WRN exonuclease activity only in 
the presence of Ku, which is phosphorylation-dependent [64]. Both groups claimed that 
WRN, DNA-PKcs, and Ku form a complex on DNA, and that DNA-PK can 
phosphorylate WRN both in vitro and in vivo [63–64].  
WRN also interacts with XRCC4-DNA ligase IV complex (X4L4). X4L4 
performs the ligation of the DNA ends that might be processed by WRN and other 
proteins. Similar to the effect of the Ku complex on WRN, X4L4 stimulates WRN 
exonuclease activity, but not helicase activity. WRN removes two nucleotides from DNA 
ends by its exonuclease activity, producing a substrate for X4L4. WRN can function as 
an NHEJ end-processing factor [65].  
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1.8 WRN functions in base excision repair (BER) 
The accumulation of oxidative DNA damage is one of the major reasons that 
cause aging. Oxidative DNA-damage lesions are repaired by the BER pathway. The first 
step of this pathway is the excision of the damaged base by a DNA glycosylase, resulting 
in an abasic (AP) site. The AP site is incised by APE-1 endonuclease, leaving a 3’ or 5’ 
abasic residue, which, in the next step, is removed by dRP. There are two sub-pathways 
in the next step: the short-patch pathway and the long-patch pathway [66].   
WRN physically and functionally interacts with many proteins involved in the 
BER pathway, including pol δ, PCNA, RPA, and FEN-1[38–44], and these interactions 
have been discussed above. WRN interacts with DNA polymerase β (pol β). Pol β is the 
major gap filling polymerase in both the short- and long-patch BER pathways. Pol β does 
not affect WRN enzymatic activities, while WRN stimulates pol β strand displacement 
DNA synthesis, and this stimulation are dependent on WRN helicase activity. WRN can 
unwind a BER substrate such as a uracil-containing oligonucleotide pre-treated with 
UDG and APE1 [67]. FEN-1 not only functions in DNA replication, but also plays a role 
in BER long-patch pathway by cleaving flap structure intermediates.  As mentioned 
above, WRN interacts with FEN-1, and stimulates FEN-1 cleavage activity [40]. WRN 
also interacts with poly ADP-ribose polymerase 1 (PARP-1), a component of the BER 
multi-protein complex [68] that is involved especially in the long-patch BER pathway by 
recruiting other proteins to the damage sites [69]. Both WRN exonuclease and helicase 
activities are inhibited by unmodified PARP-1, while auto-poly ADP-ribosylation of 
PARP-1 relieves this inhibition [70].  The PARP-1 poly ADP-ribosylation pathway is 
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deficient in WS cells after exposure to hydrogen peroxide and methyl methanesulfonate 
(MMS), indicating that PARP-1 could be activated by WRN [71] .  
1.9 WRN functions in DNA transcription 
P53 is an important transcription factor. It binds to the WRN C-terminal region 
(AA 1014–1432), and WRN binds to thep53 C-terminus [72]. WRN increases p53 
transcription activity [72], while p53 inhibits WRN exonuclease activity [73] and helicase 
activity [74-75].    
Both measuring the UTP incorporation rate and in vitro transcription experiments 
demonstrated that the transcription level in WS cells was decreased compared with wild 
type cells. Moreover, transcription from an RNA polymerase II-specific promoter showed 
a decreased rate in WS cells, but not the RNA polymerase I-specific promoter. WRN 
protein acts as a transcriptional activator, and the transcription activation domain is the 
27-amino acid direct repeat between amino acids 424–477 [76].  
WRN protein can also act as a transcriptional activator in RNA polymerase I-
mediated transcription. WRN protein is located mainly in nucleoli of unstressed cells. 
Inhibition of rDNA transcription by actinomycin D releases it from nucleoli to 
nucleoplasm. WRN interacts with a RNA polymerase I subunit, RPA40. The rDNA 
transcription level in WS cells was decreased compared with wild type cells.  These 
results suggest that WRN promotes rDNA transcription as a component of an RNA 
polymerase I -associated complex in the nucleolus [77]. 
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Figure 1.2 WRN interacts physically and functionally with many other proteins. 
WRN interacts with pol δ, RPA, FEN1, PCNA, and Topo I, which are important in DNA 
replication. WRN interacts with TRF1, TRF2, and POT1, which are important for 
telomere maintenance. WRN interacts with the Ku complex, DNA-PKcs, and the X4L4 
complex, which repair DNA DSBs through the NHEJ pathway. WRN interacts with the 
MRN complex, BRCA1, Rad51, Rad52, and BLM, which repair DNA DSBs through the 
HR pathway. WRN interacts with pol β and PPAR1, which are important components for 
DNA BER. WRN interacts with p53, which is an important transcription factor and also 
functions in DNA repair.  
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1.10 WRN is regulated by post-translational modifications (PTMs)  
As discussed above, WRN is a multifunctional protein in DNA metabolism, 
including DNA replication, recombination, repair, transcription, and telomere 
maintenance. These functions of WRN have been implicated repeatedly in the following: 
(1) Werner syndrome symptoms and WS cellular phenotype; (2) WRN enzymatic 
activities and specific substrates; (3) the WRN knockout mouse model; and (4) 
interactions between WRN and many proteins that have been demonstrated to function in 
DNA metabolism. 
The function of WRN protein can be regulated by PTMs. These modifications 
include phosphorylation, acetylation, and sumoylation. The WRN PTMs can regulate 
WRN’s catalytic activities, sub-cellular localization, and interactions with other proteins.    
1.10.1 Phosphorylation 
Phosphorylation is the first modification reported for WRN. Different kinases 
have been reported to phosphorylate WRN, including the DNA-PK complex, c-Abl, and 
ATR/ATM (ataxia telangiectasia and Rad3 related /ataxia telangiectasia mutated).  As 
discussed in the section 1.7.2 on WRN functioning in the NHEJ pathway, the DNA-PK 
complex can phosphorylate WRN both in vitro and in vivo. The phosphorylation of WRN 
by DNA-PK inhibits both helicase and exonuclease activities. WRN is phosphorylated in 
cells after treatment with bleomycin or 4NQO, and this phosphorylation is dependent on 
DNA-PK [63-64]. Cheng et al. reported that c-Abl can phosphorylate WRN on tyrosine 
residues, but the specific residues were not identified. Under normal conditions, WRN 
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interacts with c-Abl in the nucleolus. After bleomycin treatment, the interaction of WRN 
and c-Abl is disrupted, and WRN translocates from the nucleolus to the nucleoplasm. 
After a 24-hour recovery, WRN transfers back to the nucleolus. C-Abl can phosphorylate 
WRN in vitro and in vivo. Phosphorylation of WRN by c-Abl inhibits both exonuclease 
and helicase activities [78]. 
Pichierri et al. reported that ATR/ATM can also phosphorylate WRN. WRN is 
specifically phosphorylated in response to HU treatment that causes arrest of the 
replication forks. This phosphorylation is ATR/ATM dependent. ATR phosphorylates 
WRN at an early stage when abnormal structures are formed in the replication fork, while 
ATM phosphorylates WRN at a later stage when DSBs are formed. WRN foci co-localize 
with ATR after replication arrest [79]. Cheng et al. also demonstrated that WRN and 
ATM co-localize at replication foci in S-phase. Furthermore, WRN is required for ATM 
to activate the S phase checkpoint in response to ICL-induced DSBs [80].  
In summary, WRN phosphorylation is induced following many forms of DNA 
damage. Different types of DNA damages require different kinases to phosphorylate 
WRN.  WRN phosphorylation by ATM/ATR can be induced by cell cycle arrest. WRN 
phosphorylation by c-Abl is induced by bleomycin treatment which causes DNA strand 
breaks. Bleomycin can also induce DNA-PK to phosphorylate WRN. DNA-PK 
phosphorylates WRN at serine or threonine, while c-Abl phosphorylates WRN at tyrosine. 
Phosphorylation at different residues could deliver different messages in response to 
DNA damages.  
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1.10.2 Acetylation 
Blander et al. reported that WRN translocates from the nucleolus to the 
nucleoplasm in response to DNA damage. The translocation of WRN into nucleoplasmic 
foci is significantly enhanced by the deacetylase inhibitor, Trichostatin A (TSA). 
Moreover, TSA delays the re-entry of WRN into the nucleolus 24 hours later after DNA 
damage occurs. WRN is acetylated in vivo, and WRN acetylation is markedly stimulated 
by the acetyltransferase p300. Importantly, p300 augments the translocation of WRN into 
nucleoplasmic foci. These findings support the notion that WRN plays a role in the 
cellular response to DNA damage, and they suggest that the activity of WRN is 
modulated by DNA damage-induced acetylation. Acetylation might either decrease the 
interaction of WRN with proteins that retain it in the nucleolus in the absence of 
genotoxic stress or enhance its interaction with proteins that anchor it to the 
nucleoplasmic foci in response to DNA damage  [81].  
As discussed earlier, WRN stimulates pol β-dependent-strand displacement 
synthesis via its helicase activity. Recently, Muftuoglu et al. demonstrated that WRN 
acetylation stimulates strand-displacement synthesis by pol β more strongly than 
unacetylated WRN, resulting in increased long-patch BER synthesis. MMS will cause 
DNA base damage using both short patch and LP BER for repair. MMS treatment 
increases WRN acetylation in vivo in a time-dependent manner. P300 interacts with 
WRN in a DNA-independent manner, and acetylates WRN at both N-terminal (AA 1–
368) and C-terminal (AA 1072–1432) regions. Acetylation by p300 enhances WRN 
ATPase, helicase, exonuclease and DNA-binding activities in vitro [82].  
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In summary, WRN is acetylated by p300 in response to DNA damage such as 
MMS treatment. The acetylation sites are located at both the N-terminus and C-terminus 
of WRN. Acetylation induces WRN translocation from nucleolus to nucleoplasm. WRN 
acetylation by p300 regulates its ATPase, helicase, exonuclease, and DNA-binding 
activities. WRN acetylation strongly stimulates strand displacement synthesis by pol β, 
suggesting that WRN acetylation functions in the BER pathway.  
1.10.3 Sumoylation 
Using a yeast two-hybrid system, Kawabe et al. found that Ubc9 and SUMO-1 
interact with the N-terminal segment of WRN (AA 272–514) region and WRN is 
conjugated with SUMO-1 [83]. Woods et al. demonstrated that p14 Arf promotes WRN 
sumoylation. P14 Arf physically associates with WRN. P14 Arf promotes WRN 
conjugation to SUMO-1, and endogenous p14 Arf is required for WRN SUMO 
conjugation. P14 Arf expression causes nucleolus exclusion of WRN[84].  
In summary, WRN protein can be post-translational modified by phosphorylation, 
acetylation, and sumoylation. These modifications regulate WRN protein functions, 
including cellular localization and enzymatic activities. In response to different DNA 
damages, WRN is phosphorylated by DNA-PK complex, c-Abl, and/or ATM/ATR. 
WRN phosphorylation induces its translocation from the nucleolus to the nucleoplasm, 
and inhibits both its helicase and exonuclease activities. WRN is also acetylated by p300 
in response to DNA damage, and WRN acetylation induces its translocation from the 
nucleolus to the nucleoplasm. However, WRN acetylation increases WRN’s ATPase, 
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helicase, exonuclease, and DNA-binding activities, and strongly stimulates strand 
displacement synthesis by pol β. Although the function is not clear, Woods et al. 
hypothesized that sumoylation also causes WRN to be excluded from the nucleolus.  
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Figure 1.3 WRN function can be regulated by post-translational modifications. In 
response to DNA damage, WRN can be phosphorylated by DNA-PK, c-Abl, ATM and 
ATR. Phosphorylation of WRN inhibits its helicase and exonuclease, and regulates its 
cellular localization. WRN can also be modified by sumoylation, and sumoylation 
regulates its cellular localization. In response to DNA damage, WRN is acetylated by 
p300, and acetylation of WRN also regulates its cellular localization and increases its 
enzymatic activities. 
  
26 
 
 
  
27 
 
1.11 Histone acetyltransferases (HATs) and histone deacetylases (HDACs) 
WRN is regulated by many kinds of PTMs, and, especially, reversible acetylation 
is one important modification among them. The histone proteins were first reported to be 
acetylated by histone acetyltransferases (HATs). HATs transfer the acetyl group from 
acetyl-CoA to the lysine residues of histone N-terminus. Acetylation of histone by HAT 
neutralizes the positive charge of lysine, resulting in a more open and accessible 
chromatin structure to induce gene expression. Cellular proteins can also be acetylated. 
Gu et al. firstly reported that p53 can be acetylated by p300 (a HAT), and the acetylation 
of p53 dramatically stimulates its sequence-specific DNA-binding activity [85]. Since 
then, the descriptions of new cellular protein acetylation have been increased 
dramatically, most of which are transcription factors. The HATs can be divided into three 
families: the GNAT family, the MYST family, and p300/CBP. The GNAT family 
includes GCN5, PCAF, HAT1, ELP3 and HPA2. The MYST family contains Sas2, Sas3, 
Esa1, MOF, Tip60, MOX, MORF, and HBO1. CBP and p300 are structural and 
functional homologs in human [86]. 
This type of protein acetylation is reversible. Histone deacetylases (HDAC) 
remove the acetyl group from the acetylated histone, and deacetylation of histone by 
HDAC represses gene expression. There are three classes of HDACs in human: class 1, 
class 2, and class 3. Class 1 includes HDAC1–3, HDAC8 and HDAC11. Class 2 includes 
HDAC4–7 and HDAC9–10. Class 3 is also named as the Sirtuin family, and there are 
seven members in this family, named as SIRT1–7 [87]. These seven proteins are 
dissimilar in their enzymatic activities and sub-cellular localization. SIRT1, SIRT2, 
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SIRT3, and SIRT5 contain NAD-dependent deacetylase activity, while SIRT4 and SIRT6 
contain ADP-ribosyltransferase activity. SIRT1, SIRT6, and SIRT7 localize 
predominantly in the nucleus; SIRT2 is mainly in the cytoplasm; SIRT3, 4, and 5 localize 
in the mitochondria [88]. Among them, SIRT1 has been the most extensively studied.   
1.12 Sir2 extends life span 
SIRT1 is the human homolog to yeast Sir2. The yeast silent information regulator 
2 (Sir2) protein belongs to a novel family of histone deacetylases, and is involved in gene 
silencing, telomere-position effects, and cellular aging (reviewed in [89]). The NAD-
dependent deacetylase activity of Sir2 is essential for its functions, and this activity also 
connects its biological role with cellular metabolism in yeast because NAD is an 
intermediate of cellular metabolism [89-91]. Nicotinamide (NAM), the product of the 
deacetylase reaction, specially inhibits Sir2 activity [92].  
An extra copy of the Sir2 gene can increase yeast life span, while deletion of Sir2 
shortens life span [93]. Sir2 homologs have been found in a wide range of organisms 
from bacteria to human, and Sir2 homologs also increase life span in other organisms. In 
C. elegans, increased dosage of the sir-2.1 gene (the most homologous to yeast Sir2) 
extends life span [94]. In Drosophila, increasing the copy number of dSIR2, the homolog 
of yeast Sir2, also extends life span [95].  In mice, resveratrol, a SIRT1 (mammalian 
homolog of Sir2) activator, improves health and survival of mice on a high-calorie diet 
[96]. However, the effect of SIRT1 on the life span of humans’ is still not clear. Yeast 
Sir2 functions in silencing at repeated DNA sequences, including mating-type loci, 
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telomeres, and rDNA repeats [89]. Sir2 extends yeast life span by silencing rDNA repeats 
to repress extrachromosomal rDNA circles (ERCs) formation, which is produced by 
recombination and causes cell senescence [97]. 
1.13 SIRT1 as a tumor promoter 
SIRT1 is a NAD-dependent deacetylase, and many cellular proteins have been 
identified as SIRT1 substrates. The first identified target was p53. In 2001, Luo et al. 
reported that SIRT1 physically interacts with and deacetylates p53. SIRT1 represses p53 
dependent apoptosis in response to DNA damage and oxidative stress, while a dominant 
negative SIRT1 mutant increases cell sensitivity to stress [98]. This finding has been 
confirmed by other groups, and they further identified the SIRT1 deacetylation site of C-
terminal Lys 382 and demonstrated that SIRT1 deacetylation of p53 antagonizes 
PML/p53-induced cellular senescence [99-100]. Moreover, cells from SIRT1 knockout 
mice exhibit p53 hyperacetylation after DNA damage and increased ionizing radiation-
induced thymocyte apoptosis [101]. P53 is an important tumor suppressor, and due to its 
negative regulation, SIRT1 is considered as a tumor promoter.  
The FOXO3a protein is a member of the FOXO family of forkhead transcription 
factors, and it regulates apoptosis. SIRT1 interacts with and deacetylates FOXO3a. 
Deacetylation of FOXO3a represses its transcriptional activation activity and inhibits its 
ability to induce cell death [102] [103]. This is a parallel pathway regulation similar to 
p53.   
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E2F1 is another similar protein regulated by SIRT1. E2F1 is a transcription factor, 
and stimulates the transcription of several pro-apoptotic genes [104]. SIRT1 binds to and 
deacetylates E2F1. Deacetylation of E2F1 inhibits its activity as a transcription activator. 
Furthermore, E2F1 can increase SIRT1 transcription level, forming a negative-feedback 
loop [105]. 
Retinoblastoma (Rb) protein is another well-known tumor suppressor. Active Rb 
binds with E2F1, negatively regulating E2F1. When cells enter S phase, cyclin–CDK 
(cyclin-dependent kinase) complexes phosphorylate Rb, resulting in inactivating Rb. 
E2F1 is released to induce S phase specific gene expression. Rb has also been 
demonstrated to be regulated by acetylation and deacetylation. SIRT1 binds to and 
deacetylates Rb. It is  likely that SIRT1 inhibits cell cycle arrest by deacetylating Rb to 
keep it inactive [106].  
Ku70 functions not only in DNA DSBs repair through the NHEJ pathway, but 
also in repressing apoptosis by sequestering BAX (Bcl-2–associated X protein), the pro-
apoptotic factor, away from mitochondria. SIRT1 deacetylates two lysines of Ku70 at its 
C-terminus, and this deacetylation of Ku70 promotes it to sequester BAX. Therefore, 
SIRT1 can inhibit BAX-mediated apoptosis through Ku70 deacetylation [107].   
SIRT1 expression is significantly increased in murine and human prostate cancer 
cells [108]. SIRT1 is also consistently overexpressed in acute myeloid leukemia [109] 
and is highly expressed in cells from colon carcinoma patients [110]. Moreover, 
overexpression of SIRT1 is frequently observed in many kinds of nonmelanoma skin 
cancers [111]. The overexpression of SIRT1 in all these types of cancers indicates that 
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SIRT1 acts as a tumor promoter. Therefore, SIRT1 inhibitors could be developed as 
potential anticancer drugs.  
1.14 SIRT1 as a tumor suppressor  
Wang et al. investigated SIRT1 expression level in different cells. In contrast with 
the above results, they found that SIRT1 expression was reduced in many cancer cells 
compared to normal tissue, including glioblastoma, bladder carcinoma, prostate 
carcinoma, and various forms of ovarian cancers. Moreover, Wang et al. demonstrated 
that resveratrol, the SIRT1 activator, can reduce tumorigenesis. In their experimental 
system, SIRT1 seems to act as a tumor suppressor [112].  
Β-catenin is a tumor promoter, and constitutive activation of β-catenin is found in 
many types of cancers. It was reported that SIRT1 overexpression can reduce tumor 
formation in a colon cancer mouse model caused by activation of β-catenin. SIRT1 
deacetylates β-catenin, and inhibits β-catenin transcriptional activity. Therefore, SIRT1 
acts as a tumor suppressor in colon cancer by inhibiting β-catenin [113].  
NF-κB is a transcription factor that activates many genes promoting cell survival. 
SIRT1 physically interacts with the RelA/p65 subunit of NF-κB, and inhibits 
transcriptional activity by deacetylation. Cells with deacetylated NF-κB are more 
sensitive to TNF α-induced apoptosis [114].  
BRCA-1 plays an important role in DNA repair, cell cycle, transcription 
regulation, apoptosis, and ubiquitination [115]. Wang et al. found that the SIRT1 
expression level is much lower in BRCA-1- mutant cancer cells than BRCA-1-wild-type 
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cancer cells. They demonstrated that BRCA1 is a transcription activator to stimulate 
SIRT1 expression, and that restoration of SIRT1 in BRCA1 mutant cancer cells 
suppresses tumor formation. They further identified Survivin as the SIRT1 downstream 
target response to BRCA1 activation of SIRT1. Survivin promotes cell survival by 
inhibiting apoptosis. SIRT1 negatively regulates Survivin gene expression by 
deacetylating histone H3K9 at the promoter of Survivin [116].   
What is the precise role of SIRT1 in cancer? SIRT1 interacts with many cellular 
proteins, and regulates their functions through deacetylation. Deacetylation acts either 
directly on cellular proteins, or on histones to affect the promoters of genes, such as 
Survivin. These proteins are important for apoptosis or cell survival. If these proteins 
promote apoptosis, such as p53, FOXO3a, E2F1, Rb, SIRT1 acts as a tumor promoter. If 
these proteins promote cell survival, such as β-catenin, NF-κB, and Survivin, SIRT1 acts 
as a tumor suppressor.  
1.15 Regulators of SIRT1 
As discussed above, SIRT1 deacetylates many target proteins to regulate cell 
proliferation and apoptosis. In addition, SIRT1 can also be regulated by other proteins at 
different levels.  
Hypermethylated in cancer (HIC1) is a tumor suppressor. HIC1, C-terminal 
binding protein 1(CtBP1) and SIRT1 itself can form a complex that acts as a transcription 
repressor to inhibit SIRT1 gene expression. Loss of HIC1 activates SIRT1, attenuating 
p53-mediated apoptosis [117].   
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FOXO3a and p53 have been shown to be deacetylated by SIRT1, as discussed 
above. Moreover, FOXO3a and p53 can interact with each other to regulate SIRT1 
transcription. FOXO3a stimulates SIRT1 transcription through the p53-binding motifs in 
the SIRT1 promoter [118].  
HuR is a tumor suppressor. HuR can bind the 3’ UTR of the SIRT1 mRNA for 
stabilization. After DNA damage, HuR is phosphorylated, and phosphorylation of HuR 
disrupts the SIRT1 mRNA stabilization. SIRT1 protein levels are decreased, resulting in 
increased p53-mediated apoptosis [119]. This HuR-SIRT1 pathway also suggests that 
SIRT1 functions in DNA repair, which will be discussed later.  
The microRNA miR-34a is also a tumor suppressor, and it regulates SIRT1 
protein expression through binding to 3’ UTR of SIRT1 mRNA. Different from HuR, 
miR-34a inhibits SIRT1 m RNA translation, which induces p53-mediated apoptosis [120].  
Deleted in breast cancer 1 (DBC1) is another tumor suppressor to regulate SIRT1. 
DBC1 interacts with SIRT1, and inhibits SIRT1-mediated p53 deacetylation. DBC1 
knockdown reduces p53 acetylation, transcriptional activity, and p53-mediated apoptosis. 
Therefore, DBC promotes p53-mediated apoptosis through specific inhibition of SIRT1 
[121].  
Similar to DBC1, the activator regulator of SIRT1 (AROS) directly regulates 
SIRT1 function through a protein-protein interaction. Different from DBC1, AROS 
increases SIRT1 activity to deacetylate p53, and inhibits p53 transcription activity. 
AROS knockdown induces apoptosis in response to DNA damage, while AROS 
overexpression increases cell survival [122].  
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In summary, SIRT1 can be regulated by many factors at the transcription level, 
such as E2F1, HIC1-CtBP1-SIRT1 complex, FOXO3a-p53 complex, BRCA-1; at the 
mRNA translation level, such as HuR, miR-34a; or at the protein level, such as DBC1 
and AROS.  
1.16 SIRT1 in cellular metabolism 
SIRT1 is a NAD-dependent histone deacetylase. NAD is an intermediate in 
cellular metabolism.  NAD increases SIRT1 activity, while NADH and NAM inhibit it. 
NAD-dependence indicates that SIRT1 could play a role in cellular metabolism. 
Calorie restriction (CR) can extend life span in a wide range of organisms, from 
yeast to mammals. CR increases yeast life span through activation of Sir2 activity. 
Pyrazinamidase/nicotinamidase 1 (PNC1) deaminates NAM, the specific Sir2 inhibitor. 
PNC1 expression is increased in CR conditions to activate Sir2 activity, resulting in 
extended yeast life span [92].  In mice, SIRT1 expression is induced by CR [107] [123]. 
CR may extend life span through increased SIRT1 expression. The mechanism of this 
regulation remains unclear.  
The peroxisome proliferator-activated receptor gamma- coactivator-1α (PGC-1α) 
is an important transcriptional co- activator in the gluconeogenic pathway, and it induces 
gluconeogenesis gene expression [124]. Rodgers et al. reported that SIRT1 is induced in 
fasting mice, and that induced SIRT1 interacts with and deacetylates PGC-1α. 
Deacetylation of PGC-1α increases its transcription activity to induce gluconeogenic 
gene expression [123]. Therefore, SIRT1 promotes gluconeogenesis in the liver.  
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In addition to gluconeogenesis, fatty-acid oxidation is another important change 
during CR. Fats are stored in white adipose tissue (WAT). Peroxisome proliferative 
activated receptor γ (PPAR-γ) is a transcription activator that induces the expression of 
genes mediating fat storage in adipogenesis. SIRT1 interacts with NcoR (nuclear receptor 
co-repressor) and SMRT (silencing mediator of retinoid and thyroid hormone receptor), 
the cofactors of PPAR-γ, and SIRT1 represses PPAR-γ transcription activation activity 
by binding to the same DNA sequence. Therefore, SIRT1 inhibits adipogenesis and 
promotes fat mobilization through inhibition of PPAR-γ [125]. 
Type II diabetes is an age-related disease. SIRT1 promotes insulin secretion in 
pancreatic beta cells to reduce blood sugar level. Increased SIRT1 promotes insulin 
secretion in response to glucose in the pancreatic beta cells from SIRT1-overexpressed 
mice (BESTO mice) [126]. Consistent with this result, another group reported that 
knockdown of SIRT1 in pancreatic beta cells impairs insulin secretion [127]. Both groups 
identified uncoupling protein 2 (UCP2) as a SIRT1 target in this pathway. UCP2 is an 
uncoupling protein that negatively regulates insulin secretion in β cells. SIRT1 binds to 
the UCP2 promoter, and acts as a transcriptional repressor to inhibit UCP2 expression, 
resulting in reduced UCP2 and enhanced insulin secretion. 
In summary, SIRT1 plays an important role in cellular metabolism, including 
gluconeogenesis in liver, fat mobilization in WAT, and insulin secretion in the pancreas. 
SIRT1 promotes gluconeogenesis through activating PGC-1 by deacetylation. SIRT1 
increases fat mobilization through binding with PPAR-γ cofactors to inhibit PPAR-γ 
transcriptional activation activity. SIRT1 stimulates insulin secretion through binding to 
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the UCP2 promoter as a transcriptional repressor to inhibit UCP2 protein expression. CR 
may extend life span through increased SIRT1 expression, and increased SIRT1 may 
function through the three pathways discussed above to extend life span.  
1.17  SIRT1 in DNA damage response 
NBS1 is an important DNA repair protein. Mutations of the NBS1 gene causes 
Nijmegen breakage syndrome. NBS1, MRE11, and RAD50 form MRN complex, which 
functions in DNA DSB repair through the HR and NHEJ pathways. SIRT1 associates 
with the MRN complexes. SIRT1 deacetylates NBS1 protein and keeps it in a 
hypoacetylation state that is required for NBS1 Ser343 phosphorylation induced by IR. 
Phosphorylation of NBS1 is required for both S-phase checkpoint activation and efficient 
DNA repair [128]. 
This SIRT1-NBS1 function in DNA repair was supported by Oberdoerffer et al., 
and they claimed that SIRT1 recruits Rad51 and NBS1 to the DNA-DSB sites. 
Furthermore, they demonstrated that under normal conditions, SIRT1 silences age-related 
gene expression. In response to DNA damage, SIRT1 relocates from the highly repetitive 
DNA sites, such as pericentromeric major satellite repeats in mouse ES cells,  to the sites 
of DSBs, and this relocation is dependent on ATM. SIRT1 modifies the chromatin near 
the DSBs to facilitate repair, resulting in increased genome stability and tumor 
suppression. On the other hand, after DNA damage is repaired, not all SIRT1 proteins go 
back to highly repetitive DNA sites. Those SIRT1-targeted age-related genes will express 
to cause aging because SIRT1 is deregulated, supporting the role of SIRT1 as a longevity 
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protein [129]. This SIRT1 translocation is similar to its homolog in yeast. Yeast Sir2 
translocates from telomeres to DNA DSB sites, together with Sir3, Sir4 and Ku proteins 
for DNA DSB repair through the NHEJ pathway [130]. 
SIRT1 also interacts with and deacetylates many other proteins important to DNA 
repair, including p53 and Ku70, which have been discussed above. Moreover, SIRT1 is 
also regulated by many other DNA-repair proteins, including p53, BRCA1, HuR, AROS 
and DBC1. Wang et al. reported that SIRT1 deficiency causes cell-cycle abnormalities 
and impaired DNA-damage repair. In addition, SIRT1-knockout mice display incomplete 
chromosome condensation, chromosome instability, and impaired heterochromatin 
formation, suggesting that SIRT1 plays an important role in maintaining genomic 
stability [112]. 
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Figure 1.4 Regulators of SIRT1 and SIRT1 regulating other proteins. SIRT1 can be 
regulated by many factors and by many mechanisms: at the transcription level, such as by 
E2F1, HIC1-CtBP1-SIRT1 complex, FOXO3a-p53 complex, BRCA1; at the mRNA 
translation level, such as HuR, miR-34a; at the protein level, such as DBC1 and AROS. 
On the other hand, SIRT1 regulates other proteins functions in different cellular 
processes. SIRT1 acts as a tumor promoter by regulating proteins that include p53, 
FOXO3a, E2F1, Rb and Ku70. SIRT1 acts as a tumor suppressor by regulating proteins 
that include β-catenin, NF-κB, and Survivin. SIRT1 also functions with proteins in DNA 
repair, such as NBS1, p53, Ku70, BRCA1, HuR, AROS and DBC1. CR induces SIRT1 
expression and SIRT1 functions in cellular metabolism by regulating proteins, such as 
PGC-1α, PPAR-γ and UCP2.  
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1.18  Concluding Remarks 
As discussed above, both WRN and SIRT1 are multifunctional proteins. It is very 
possible that WRN and SIRT1 could function together in some cellular processes 
including aging, cancers, telomere maintenance, cellular metabolism, cellular senescence, 
and DNA repair. The most direct evidence is that WRN can be acetylated and SIRT1 is a 
NAD-dependent histone deacetylase. This hypothesis has been supported by the 
following evidences. First, WS patients display premature aging [1], while SIRT1 is 
considered as a longevity protein. Although it has not been proven that SIRT1 can extend 
human’ life, yeast Sir2 and its homologs can extend life span in a wide range of lower 
organisms [93-96]. WRN and SIRT1 could function together in the normal aging process. 
Second, WS patients are predisposed to cancers [1]. WRN protein is a tumor suppressor, 
and epigenetic inactivation of the WRN gene has been reported in human cancers [131]. 
SIRT1 also plays a role in tumorigenesis. It is very likely that WRN and SIRT1 could 
function together in tumorigenesis. Third, WRN protein plays an important role in 
telomere maintenance (reviewed in [132]). Yeast Sir2 mediates silencing at telomeres 
[89], and human SIRT1 also silences repetitive DNA [129]. WRN and SIRT1 could 
function together in telomere maintenance. Fourth, WS patients develop type II diabetes 
[1], while SIRT1 can stimulate insulin secretion in pancreatic beta cells by inhibiting 
UCP2 expressing [126-127]. Fifth, WS cells have a reduced life span and undergo 
premature replicative senescence much faster than do normal cells [2]. SIRT1 can also 
regulate premature cellular senescence induced by PML and p53 [100]. 
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Finally, cells from SIRT1 knockout mice display increased chromosomal 
instability and impaired DNA repair [112], while WS cells show increased genomic 
instability and are hypersensitive to DNA-damaging drugs [3-6]. These phenotypes 
suggest WRN and SIRT1 might function together in DNA repair. WRN accumulates at 
the sites of DNA DSBs [48], while SIRT1 re-localizes from the highly repetitive DNA 
sites to DNA DSB sites [129]. Furthermore, both WRN and SIRT1 proteins interact 
physically and functionally with many common proteins, including Ku complex [59-61] 
[107], NBS1 [50] [128], BRCA1 [52] [116], and p53 [72-75] [98-100], which are all 
important in DNA repair.  
The objective of my thesis research is to investigate how acetylation and 
deacetylation regulate WRN protein function in response to DNA damage, and the role of 
SIRT1 protein in this process. Beyond that, we will continue to study the WRN-SIRT1 
pathway in telomere maintenance and cellular senescence. Our studies will extend the 
current knowledge of the functions of WRN protein in some cellular processes, and 
regulation of WRN functions by acetylation and SIRT1-mediated deacetylation, and help 
us to better understand the molecular mechanism for targeting SIRT1 as a therapeutic 
treatment.  
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CHAPTER 2: Acetylation and deacetylation of WRN regulate its stability 
through the ubiquitin-proteasome pathway 
2.1  Abstract 
WRN is a multi-functional protein in DNA metabolism, including DNA 
replication, recombination, repair, transcription, and telomere maintenance. WRN has 
been reported to physically and functionally interact with many proteins.  SIRT1 is the 
human homolog to yeast Sir2, and it is a NAD-dependent histone deacetylase. SIRT1 
interacts with and deacetylates many proteins, including p53. SIRT1 regulates other 
proteins’ functions through deacetylation. CBP/p300 can acetylate not only histones but 
also many cellular proteins, and acetylation can regulate protein stability through 
different mechanisms.   
Here, we show that SIRT1 interacts with WRN both in vitro and in vivo and this 
interaction is enhanced after DNA damage.WRN can be acetylated by acetyltransferase 
CBP/p300 in vitro and in vivo, and we identified 6 lysine residues as major acetylation 
sites. SIRT1 can deacetylate WRN both in vitro and in vivo. Interestingly, WRN 
acetylation can increase its protein stability. SIRT1-mediated deacetylation of WRN 
reverses this effect. CBP dramatically increases the half-life of wild type WRN, while 
mutation of these 6 lysine residues (WRN-6KR) abrogates this increase. We further 
found that WRN stability is regulated by the ubiquitination pathway. WRN acetylation by 
CBP significantly reduces its ubiquitination, while SIRT1 decreases its ubiquitination. 
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2.2 Introduction 
WRN is a 1,432-amino-acid (160 kD) protein and a member of the human RECQ 
helicase family [8]. There are five known members in this family, including RecQ1, 
BLM, WRN, RecQ4 and RecQ5 [9]. Mutations of WRN gene will cause WS, a rare 
autosomal recessive disorder [1].  
WRN protein has been extensively studied during the last decade. It has been 
reported that WRN protein physically and functionally interacts with many other proteins. 
DNA polymerase δ [42], PCNA [44], RPA [38], and FEN-1 [133] are important proteins 
for DNA replication. MRN complex [50], RAD51 [53], RAD52 [55], BRCA1 [52], and 
BLM [57] repair DNA DSBs through HR pathway; while Ku complex [59], DNA-PKcs 
[63], and X4L4 complex [65] repair DNA DSBs through NHEJ pathway. DNA 
polymerase β [67] and PARP-1 [70]take part in DNA BER. TRF1, TRF2 [21] and POT1 
[34] are components of a complex named as the telosome or shelterin, which protects the 
telomeres. All of these interactions suggest that WRN may play a role in DNA 
metabolism.  
CBP and p300 are structural and functional homologs in humans. P300/CBP is 
histone acetyltransferase (HAT). HATs can transfer an acetyl group from acetyl-CoA to 
histones’ N-terminal tail, resulting in a more open and accessible chromatin structure to 
induce gene expression [86]. In addition to histones, p300/CBP can also acetylate other 
cellular proteins. Many of these proteins are transcription factors, such as p53, and 
acetylation of p53 increases its transcription activation activity [85].  
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It has been extensively reported that acetylation can regulate the stability of 
proteins, but the mechanism is not certain. Proteins can be degraded through the 
ubiquitination-proteasome pathway, and both acetylation and ubiquitination target lysines 
for modification. The most straightforward hypothesis is that acetylation can stabilize 
protein through inhibition of ubiquitination by competing with the same lysines. Actually, 
this is true for p53. P53 C-terminal acetylation sites K320, 372, 373, 381 and 382 are also 
ubiquitination sites targeted by E4F1 or MDM2 [134], and acetylation of the C-terminal 
domain of p53 is sufficient to abrogate its ubiquitination [135]. Other proteins using this 
mechanism to regulate stability include p53 homolog p73 [136], Smad7 (Mothers against 
decapentaplegic homolog 7) [137], c-MYC [138], SREBPs (sterol regulatory element 
binding proteins) [139] and Runx3 (Runt domain transcription factor 3) [140].  
Acetylation can also stabilize protein through other mechanisms. For example, in the ETS 
transcription factor ER81, acetylation sites are not ubiquitination sites. It is speculated 
that ER81 acetylation either induces its conformation change, or increases its interaction 
with other proteins to shield it from being recognized by ubiquitin ligases [141]. 
Acetylation can decrease protein stability through different mechanisms. 
Acetylation can increase protein degradation through the ubiquitination-proteasome 
pathway. Acetylation of HIF-1 α (Hypoxia-inducible factor 1 α) facilitates its interaction 
with the E3 ligase pVHL (Von Hippel–Lindau tumor suppressor), resulting in increased 
degradation [142].  Similarly, Tip60-mediated acetylation of Rb induces its proteasomal 
degradation [143].  Acetylation can also destabilize proteins through a proteasome-
independent mechanism. Hsp90 (heat shock protein 90) is a chaperone, and is required 
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for the stabilization of its client proteins, such as Bcr-Abl. Acetylation of Hsp90 disrupts 
Hsp90 and Bcr-Abl interaction, resulting in Bcr-Abl degradation [144].   
SIRT1 is human homolog to yeast Sir2, and SIRT1 is a NAD-dependent histone 
deacetylase [88]. SIRT1 has been reported to physically and functionally interact with 
many other proteins, which are important for cell proliferation and cell apoptosis 
including p53 [98], FOXO3a [102], Ku70 [107], E2F1 [105], NF-κB [114], β-catenin 
[113], and Survivin [116]. SIRT1 regulates these proteins’ functions through 
deacetylation. SIRT1 deacetylation of p53 attenuates p53-mediated cell arrest and 
apoptosis [98].  SIRT1 can also deacetylate some DNA repair proteins, including Ku70 
[107] and NBS1[145]. Moreover, SIRT1 deacetylates some proteins to regulate cell 
metabolism, including PGC-1α [123], PPAR-γ [125], and UCP2 [127]. SIRT1 promotes 
gluconeogenesis through activating PGC-1α by deacetylation. SIRT1 increases fat 
mobilization through binding with PPAR-γ cofactors to inhibit PPAR-γ transcriptional 
activation activity. SIRT1 stimulates insulin secretion through binding to UCP2 promoter 
as a transcriptional repressor to inhibit UCP2 protein expression. 
SIRT1 can also regulate protein stability through deacetylation. SIRT1 decreases 
c-MYC stability via catalyzing its deacetylation [146]. P53 can be deacetylated by SIRT1 
[98] and HDAC1 [147]. Deacetylation of p53 promotes MDM2-mediated p53 
degradation [147]. SIRT1 deacetylates RelA subunit of NF-κB at K310, resulting in 
increases its methylation at K314 and 315, leading to its ubiquitination and degradation 
[148].  
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Recently, Kahyo and colleagues reported that SIRT1 can stabilize WRN protein 
by deacetylation. By treating the cells with sirtinol, a specific SIRT1 inhibitor, WRN 
protein level and half life were decreased. Furthermore, they demonstrated that WRN 
protein is degraded through the ubiquitin-proteasome pathway, and sirtinol treatment 
increased WRN ubiquitination. Lastly, they showed that the WRN protein level is 
decreased, not the mRNA level, in the livers of SIRT1 knockout mice [149].  
In our study, we found that SIRT1 can interact with WRN in vitro and in vivo. In 
order to further understand the regulation of WRN acetylation and its stability, we 
identified WRN acetylation sites and made a WRN mutant that could not be acetylated to 
test its stability. We found that WRN acetylation can increase its protein stability. 
Deacetylation of WRN by SIRT1 can reverse this effect. CBP dramatically increases the 
half-life of wild type WRN, while this increase is abrogated with the WRN acetylation 
mutant. We further found that WRN stability is regulated by the ubiquitination pathway, 
and WRN acetylation by CBP can dramatically reduce its ubiquitination.  
  
47 
 
2.3 Results 
SIRT1 interacts with WRN both in vitro and in vivo  
The interaction of SIRT1 and WRN was first tested by a transient transfection 
assay. Either Flag-tagged SIRT1 with WRN or Flag-tagged WRN with SIRT1 are 
transfected into HEK293T cells. After anti-Flag M2 beads immunoprecipitation, the IP 
products were subjected to SDS-PAGE and a western blot with anti-WRN and anti-
SIRT1 antibodies. As shown in Fig. 2.1 A, SIRT1 protein was clearly co-
immunoprecipitated with Flag-WRN (lane 1, upper panel). WRN protein was also clearly 
co-immunoprecipitated with Flag-SIRT1 (Fig. 2.1 B lane 1, upper panel).  
Then we tested whether SIRT1 directly interacted with WRN and tried to recover 
the specific region of WRN mediating this interaction. GST fusion proteins were 
generated for the N-terminal (GST-WRNNT), central (GST-WRNM), and C-terminal 
(GST-WRNCT) regions of WRN and immobilized on GST-agarose. As shown in Fig. 2.1 
D, [35S]-labeled in vitro translated SIRT1 strongly bound to immobilized GST-WRNCT 
but not to immobilized GST alone (lane 3 vs. lane 4). Moreover, SIRT1 only bound to the 
C-terminal domain of WRN (GST-WRNCT), as no binding to N-terminal domain (GST-
WRNNT) and central helicase domain (GST-WRNM) was detected (lanes 1-3). Thus, 
these findings demonstrate that SIRT1 interacts with WRN both in vitro and in vivo, 
apparently through binding to the C-terminal region of WRN. 
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Figure 2.1 SIRT1 interacts with WRN both in vitro and in vivo. A) Transient 
transfection assay for WRN and SIRT1 interaction. SIRT1 was either transfected alone 
(lanes 2) or with Flag-tagged WRN (lane 1) into HEK293 cells. After 
immunoprecipitation with Flag M2 beads, the IP products were subjected to SDS-PAGE 
and western blotting with anti-WRN and anti-SIRT1 antibodies. The input also showed 
the western blot of anti-β-actin as loading control (bottom panel). B) Reverse transient 
transfection assay for WRN and SIRT1 interaction. WRN was either transfected alone 
(lanes 2) or with Flag-tagged SIRT1 (lane 1) into HEK293 cells. After 
immunoprecipitation with Flag M2 beads, the IP products were subjected to SDS-PAGE 
and western blotting with anti-WRN and anti-SIRT1 antibodies. The input also showed 
the western blot of anti-β-actin as loading control (bottom panel). C) GST-WRNNT, 
GST-WRNM, GST-WRNCT, and GST proteins were purified. The GST-tagged 
constructs were made as indicated. D) GST pulldown assay. GST-WRN proteins were 
incubated with [35S] labeled in vitro translated SIRT1. After incubation and wash, GST 
beads were eluted with SDS-sample buffer and elutes were subjected to SDS-PAGE and 
autoradiography. The input was 10% of the labeled SIRT1 in each reaction. The lower 
panel was the coomassie blue staining of the same proteins. 
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We next tested whether endogenous WRN can interact with endogenous SIRT1. 
HEK293 cells were immunoprecipitated with an anti-WRN polyclonal antibody or 
control IgG. Endogenous SIRT1 can clearly be co-immunoprecipitated with WRN (Fig. 
2.2 A, lane 5 vs. lane 8). Interestingly, this interaction was increased in the cells after a 6 
h treatment with etoposide or H2O2 (Fig. 2.2 A, lanes 5–7), suggesting that the possible 
regulation of WRN by SIRT1 is enhanced after DNA damage.  
Then, we did reverse co-immunoprecipitation experiment for endogenous WRN 
and SIRT1. We used anti-SIRT1 antibody to pull down endogenous SIRT1, and used IgG 
as a negative control. Clearly, endogenous WRN can be co-immunoprecipitated with 
SIRT1 (Fig. 2.2 B, lane 2 vs. lane 1). Similar as the result in Fig. 2.2 A, etoposide 
treatment enhanced this interaction (Fig. 2.2 B, lane 3 vs. lane 2).  
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Figure 2.2 Endogenous SIRT1 interacts with endogenous WRN, and the interaction 
is enhanced after DNA damage treatment. A) HEK293 cell lysates were 
immunoprecipitated with control rabbit IgG (lane 8) or anti-WRN antibody without (lane 
5) or after treatment with H2O2 (lane 6) or 20 μM etoposide (lane 7). The IP products 
were subjected to SDS-PAGE and western blotting with anti-WRN antibody (upper panel) 
or anti-SIRT1 antibody (lower panel). Lanes 1–4 showed 5% of input for each IP. B) 
Reverse Co-IP. Lysates from 293T cells, either untreated (lanes 1, 2) or treated with 20 
μM etoposide (lane 3), were immunoprecipitated with control rabbit IgG (lane1) or anti-
SIRT1 antibody (lane 2, 3). The IP products were subjected to SDS-PAGE and a western 
blot with anti-WRN antibody (upper panel) or anti-SIRT1 antibody (lower panel).  
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WRN can be acetylated by CBP and p300  
Considering SIRT1 is a NAD-dependent histone deacetylase which interacts with 
WRN, we considered whether SIRT1 deacetylates WRN. Because protein acetylation and 
deacetylation is a process of balance, the first question is if WRN can be acetylated. 
Blander and colleagues reported that WRN is acetylated in cells by transfecting WRN 
expression plasmid alone or with p300 expression plasmid into HEK293 cells. After in 
vivo labeling with radioactive acetate, they detected WRN acetylation, which can be 
augmented by co-transfecting p300 [81].  
Using a different approach, we also detected WRN acetylation (Fig. 2.3). In our 
approach, Flag-tagged WRN expression plasmid was transfected alone or together with 
different HATs expression vectors, including CBP, PCAF, p300, Tip60, and MOF into 
293T cells. After immunoprecipitation with anti-Flag M2 beads, we detected WRN 
acetylation by western blot with anti-acetylated lysine antibody.  As shown in Fig. 2.3, 
we can clearly detect WRN acetylation when WRN was co-transfected with CBP or p300 
(lanes 2, 3), but not the other HATs, indicating that CBP/p300 are the major 
acetyltransferases for WRN acetylation.  
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Figure 2.3 WRN is acetylated by CBP and p300.  Acetylation assay in 293T cells with 
different acetyltransferases. Flag-tagged WRN was co-transfected with vector, or 
different histone acetyltransferases, including CBP, PCAF, p300, Tip60, and MOF into 
293T cells. After IP with anti-flag M2 beads, the IP products were subjected to SDS-
PAGE for separation. Western blot analysis was performed with anti-acetylated lysine 
antibody (Upper panel) or with anti-WRN antibody. The lower panel is the different 
acetyltransferase proteins, which were detected by western blot using anti-Flag, HA 
mixed antibodies. The experiment was repeated at least three times. 
 
 
  
55 
 
 
  
56 
 
Identification of WRN acetylation sites 
Next, we tried to map the WRN acetylation sites. Because different 
acetyltransferases may acetylate different sites of their target proteins, to identify WRN 
acetylation sites, we purified acetylated WRN protein after co-transfection of FLAG-
tagged WRN with both CBP and p300. The protein was digested with trypsin and 
analyzed by both MALDI-TOF and LC-ESI MS/MS. A number of acetylated lysine 
containing peptides were identified (Fig. 2.4 A). The acetylated lysine residues in WRN 
were K366, K887, K1117, K1127, K1389, and K1413. 
We used the in cell acetylation assay to confirm the WRN acetylation sites 
identified by mass spectrometry analysis. Our strategy was to mutate these putatively 
acetylated lysines to arginines, since arginine cannot be acetylated but retains the positive 
charge. First, single mutations were made on all 6 lysines. Single mutations of K1117R 
and K1389R showed significant reductions in the overall level of WRN acetylation (Fig. 
2.4 B, lanes 4 and 6). Then, the double mutation constructs K1117/1127R and 
K1389/1413R were constructed. Both double mutants showed decreased WRN 
acetylation (Fig. 2.4 C, lanes 2 and 3). Furthermore, upon expression of the triple mutant 
K1127/1389/1413R and quadruple mutant K1117/1127/1389/1413R, both mutants 
showed further decreased WRN acetylation level but weak acetylation was detected (Fig. 
2.4 C, lanes 4 and 5). We finally mutated all of these six lysines to arginines 
(K366/887/1117/1127/1389/1413R). WRN acetylation was at the lowest level detected in 
this WRN-6KR mutant (Fig. 2.4 C, lane 6), indicating that all 6 lysines are subject to 
WRN acetylation.  
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Figure 2.4 Identify WRN acetylation sites. A) Mass-spectrometry analyses identify the 
WRN acetylation sites. Acetylated WRN protein was purified by co-transfection of 
FLAG-tagged WRN with both CBP and p300. The protein was digested with trypsin and 
analyzed by both MALDI-TOF and LC-ESI MS/MS. Scores of ESI or MALDI QIT were 
shown. Mascot scores greater than 40 or found in both MALDI and ESI were most 
confident for the true detection of acetylation. B) Confirmation of WRN acetylation sites 
in cells using acetylation assay. WRN-WT or single mutant was transfected with CBP 
into HEK293 cells. After immunoprecipitation with FLAG M2 beads, the IP products 
were subjected to SDS-PAGE and western blotting with anti-acetylated lysine and anti-
WRN antibodies. C) WRN-WT or double mutant or triple mutant or quadruple mutant or 
6KR mutant was transfected with CBP into cells. The same assay described in B was 
performed. All the experiments were repeated at least three times. The bands of WRN 
proteins were quantified by ImageJ software. 
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SIRT1 deacetylates WRN both in vitro and in vivo 
Now, we want to answer the question whether SIRT1 can deacetylate WRN? 
Acetylated Flag-WRN was purified from HEK293T cells, and SIRT1 was stably 
transfected into a cell line and subsequently purified. This in vitro deacetylation assay 
was performed by incubating SIRT1 with purified acetylated Flag-WRN at 300C for 1 h 
followed by SDS-PAGE and western blot with anti-acetylated lysine antibody. As shown 
in Figure 2.5 A, WRN can be deacetylated by SIRT1 (lane 4). The deacetylation is NAD 
dependent (lane 4 vs. lane 2) as expected for SIRT1-mediated deacetylation. However, 
the deacetylation activity was completely inhibited in the presence of NAM (lane 5 vs. 
lane 4), the specific SIRT1 inhibitor.  
We also examined whether SIRT1 could mediate WRN deacetylation in cells. A 
high level of acetylated WRN was found in HEK293 cells co-transfected with CBP and 
WRN (Fig. 2.5 B, lane 1); however, WRN acetylation levels were progressively 
decreased by increasing expression of SIRT1 (Fig. 2.5 B, lanes 2–4). In contrast, this 
level of WRN acetylation was not reduced by transfection of a deacetylase-deficient 
SIRT1-363Y point mutant (Fig. 2.5 B, lane 5).  These results indicate that WRN is a 
specific target for SIRT1 deacetylase activity.    
We also examined endogenous WRN acetylation status after siRNA-mediated 
reduction of SIRT1 protein level in HEK293T cells. After immunoprecipitation with 
antibody specific for acetylated WRN, we clearly detected a significantly increased level 
of acetylated WRN when SIRT1 was down-regulated (Fig. 2.5 C, lane 2 vs. lane 1) 
indicating that SIRT1 is the specific deacetylase for WRN protein in cells.     
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Figure 2.5 SIRT1 deacetylates WRN in vitro and in vivo. A) In vitro deacetylation 
assay for WRN. Acetylated WRN protein was purified from HEK293 cells as described 
in Fig 2.3 A. SIRT1 was Flag-tagged and purified from a stable cell line by 
immunoprecipitation with anti-Flag M2 beads. The indicated components were incubated 
at 300C for 1 h followed by SDS-PAGE and western blotting with anti-acetylated lysine. 
B) WRN deacetylation assay in the cells. HEK293 cells were co-transfected with Flag-
WRN and CBP with normal SIRT1, mutant SIRT1-363Y, or controls as indicated. After 
anti-Flag M2 beads immunoprecipitation, the IP products were subjected to SDS-PAGE 
and a western blot with anti-acetylated lysine, anti-WRN and anti-SIRT1 antibodies. C) 
SIRT1 down-regulation increases WRN acetylation. HEK293 cells were transfected with 
siRNA for SIRT1 or GFP, cell lysates were immunoprecipitated with anti-acetylated 
WRN specific antibody. IP products were western blotted with anti-WRN monoclonal 
antibody (upper panel). Cell lysates were also examined for SIRT1, WRN and β-actin as 
control. 
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CBP stabilizes WRN protein 
When acetylation assays were performed, we always noticed that co-transfection 
of WRN and CBP not only resulted in WRN acetylation (Fig. 2.6 A, lane 2, lower panel), 
but also led to a significant increase in the level of WRN protein (Fig. 2.6 A, lane 2 vs. 
lane 1, upper panel). We further investigated whether CBP can stabilize the endogenous 
WRN level by over-expressing CBP in HEK293 cells; indeed, endogenous WRN was 
increased by CBP over-expression (Fig. 2.6 B, lane 2 vs. lane 1). In U2OS cells with 
p300 stably knocked down, CBP protein level was increased because of compensation. 
We also checked the endogenous WRN protein levels in these stable cell lines. 
Endogenous WRN protein level was also increased in p300 stably knocked down U2OS 
cells compared to control cells, which was consistent with increased CBP protein level 
(Fig. 2.6 C, lane 3 vs. lane1). We further examined if CBP can affect the half-life of 
WRN. Vector or CBP were transfected into HEK293 cells. Cells were treated with 
cycloheximide (CHX) for the indicated time and the levels of endogenous WRN protein 
were detected by western blotting. CBP indeed increased the half-life of endogenous 
WRN (Fig. 2.8 D, lanes 5-8 vs. lanes 1-4, upper panel). We also down-regulated CBP by 
siRNA and examined its effect on WRN. Our results show that WRN protein level was 
slightly reduced after CBP knockdown (Fig. 2.6 E).  
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Figure 2.6 CBP stabilizes WRN protein. A) Exogenous WRN protein level was 
increased by CBP. Flag-WRN alone or with CBP was transfected into HEK293 cells. 
After IP with FLAG M2 beads, the products were subjected to SDS-PAGE and western 
blot with anti-WRN and anti-acetylated lysine antibodies. B) Endogenous WRN protein 
level was increased by CBP. Vector or CBP were transfected into HEK293 cells. Cell 
lysates were analyzed by western blot with anti-WRN and anti-β-actin antibodies. C) In 
U2OS cells with p300 stably knocked down, increased endogenous WRN protein level 
was consistent with increased endogenous CBP protein levels. Cell lysates were analyzed 
by western blot with anti-WRN, anti-CBP, and anti-β-actin antibodies. D) CBP increased 
endogenous WRN half-life. Vector or CBP were transfected into HEK293 cells. Cells 
were treated with cycloheximide for the indicated time. Cell lysates were analyzed by 
western blot with anti-WRN and anti-β-actin antibodies. E) Endogenous WRN protein 
level was decreased by CBP knockdown. HEK293 cells were transfected with siRNA for 
CBP or GFP. Cell lysates were analyzed by western blot with anti-WRN, anti-CBP, and 
anti-β-actin antibodies.  
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SIRT1 destabilizes WRN protein  
We previously found that the NAD-dependent histone deacetylase SIRT1 can 
specifically deacetylate WRN. Here, we also examined if SIRT1 can reverse CBP 
stabilization of WRN. Flag-WRN and SIRT1 (or vectors alone) were co-transfected into 
HEK293 cells and the level of WRN was detected by western blotting. SIRT1 over-
expression clearly decreased the WRN protein level (Fig. 2.7 A, lane 2 vs. lane 1, upper 
panel). We further examined endogenous WRN protein level by SIRT1 expression. As 
expected, over-expression of SIRT1 in cells also reduced the level of endogenous WRN 
(Fig. 2.7 B, lane 2 vs. lane 1, upper panel). We then knocked down endogenous SIRT1 by 
siRNA in the cells (Fig. 2.7 C, lane 2, middle panel); endogenous WRN levels were 
clearly increased (Fig. 2.7 C, lane 2 vs. lane 1, upper panel). These results indicate that 
WRN protein is stabilized through CBP-mediated posttranslational modification, and 
SIRT1 can reverse this effect.  
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Figure 2.7 SIRT1 destabilizes WRN protein. A) Flag-WRN alone or with SIRT1 was 
transfected into HEK293 cells. Cell lysates were subjected to SDS-PAGE and western 
blotting with anti-WRN, anti-SIRT1 and anti-β-Actin antibodies. B) Endogenous WRN 
protein level was decreased by SIRT1. Vector or SIRT1 was transfected into HEK293 
cells. Cell lysates were analyzed by western blot with anti-WRN, anti-SIRT1, and anti-β-
actin antibodies. C) Endogenous WRN protein level was increased by SIRT1 knockdown. 
HEK293 cells were transfected with siRNA for SIRT1 or GFP. Cell lysates were 
analyzed by western blot with anti-WRN, anti-SIRT1, and anti-β-actin antibodies. All the 
experiments were repeated at least three times. The bands of WRN proteins were 
quantified by ImageJ software. 
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CBP stabilizes WRN protein through acetylation. 
Since CBP is also a transcriptional co-activator, it is possible that CBP may 
increase WRN gene expression. We examined the WRN mRNA level by Real-time PCR 
in HEK293 cells transfected with CBP or empty vector. When RNA was isolated 12 
hours after transfection, WRN mRNA levels did not significantly change (Fig. 2.8 A), 
indicating that the observed increase in WRN protein is the result of a CBP-mediated 
posttranslational event. Our finding that CBP stabilizes WRN through posttranslational 
modification has been further examined by expressing a WRN acetylation mutant in cells. 
Vectors expressing FLAG-WRN-wt or FLAG-WRN-6KR were co-transfected with 
empty vector, CBP- or SIRT1-expression vectors into HEK293 cells and the levels of 
WRN protein were detected by western blotting. As expected, CBP increases WRN-wt 
levels, while SIRT1 reverses this effect (Fig. 2.8 B, lanes 1-3, upper panel). In contrast, 
CBP failed to increase the level of mutant WRN-6KR protein (Fig. 2.8 B, lane 5 vs. lane 
4, upper panel), while SIRT1 co-transfection only showed a slight decrease in WRN-6KR 
protein levels (Fig. 2.8 B, lane 6 vs. lane 4, upper panel), indicating that the acetylation 
mutant abrogated the ability of CBP to stabilize WRN. We then examined the effect of 
CBP on wild type WRN and acetylation mutant 6KR. FLAG-WRN-wt or 6KR alone or 
with CBP were transfected into HEK293T cells. The same assay was performed to 
examine the half-life of WRN protein. CBP increased the half-life of WRN-wt (Fig. 2.8 
C, lanes 5-8 vs. lanes 1-4, upper panel) but failed to increase that of WRN-6KR (Fig. 
2.8D, lanes 5-8 vs. lanes 1-4, upper panel). All these data demonstrate that CBP stabilizes 
WRN protein through acetylation.  
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Figure 2.8 CBP stabilizes WRN protein through acetylation. A) Vector or CBP was 
transfected into HEK293 cells. Total RNA was isolated and cDNA were synthesized 
using the Superscript III enzyme. Real-time PCR was performed to detect the WRN 
mRNA level. B) WRN-WT or WRN-6KR was transfected with vector, CBP or SIRT1 
into HEK293T cells. Cell lysates were analyzed by western blot with anti-FLAG and 
anti-β-actin antibodies. WRN acetylation levels were detected by anti-acetylated lysine 
antibody. C) Flag-WRN-WT alone or with CBP was transfected into HEK293 cells. Cells 
were treated with cycloheximide for the indicated time. Cell lysates were analyzed by 
western blot with anti-FLAG and anti-β-actin antibodies. D) CBP was unable to increase 
WRN-6KR half-life. Flag-WRN-6KR alone or with CBP was transfected into HEK293 
cells. Cells were treated with cycloheximide for the indicated time. Cell lysates were 
analyzed by western blot with anti-FLAG and anti-β-actin antibodies.  
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Acetylation stabilizes WRN protein through inhibiting its ubiquitination 
WRN has been reported to be regulated by the ubiquitination pathway [149]. We 
further examined if acetylation stabilizes WRN protein by inhibiting its ubiquitination. 
FLAG-WRN alone or with HA-Ub was transfected into HEK293 cells. After 
immunoprecipitation with FLAG M2 beads, the IP products were subjected to SDS-
PAGE and western blotting with anti-HA and anti-WRN antibodies. WRN ubiquitination 
could be clearly detected (Fig. 2.9 A, lane 2 vs. lane 1) and was strongly enhanced by the 
proteasome inhibitor MG132 (Fig. 2.9 B, lane 5 vs. lane 3). The acetylation mutant 
WRN-6KR was also examined by this ubiquitination assay. FLAG-WRN-wt or –WRN-
6KR was transfected with vector or HA-Ub into HEK293 cells. WRN-6KR showed 
stronger ubiquitination than WRN-wt (Fig. 2.9 C, lane 5 vs. lane 3), indicating that WRN 
acetylation and ubiquitination do not compete for the same set of lysine residues.  
The effect of CBP and SIRT1 on WRN ubiquitination was further investigated. 
Flag-WRN was co-transfected with vector, HA-Ub, CBP and HA-Ub, or SIRT1 and HA-
Ub into HEK293 cells. Co-transfection of CBP clearly decreased WRN ubiquitination 
(Fig. 2.9 D, lane 4 vs. lane 3), while SIRT1 showed the opposite effect (Fig. 2.9 D, lane 5 
vs. lane 4). These results suggest that CBP and SIRT1 regulate WRN ubiquitination 
through acetylation/deacetylation. 
  
72 
 
Figure 2.9 WRN acetylation inhibits its ubiquitination. A) WRN can be modified by 
ubiquitination. Flag-WRN alone or with HA-Ub was transfected into HEK293 cells. 
After immunoprecipitation with FLAG M2 beads, the IP products were subjected to 
SDS-PAGE and western blot with anti-HA and anti-WRN antibodies. B) MG132 
enhanced WRN ubiquitination. Flag-WRN alone or with HA-Ub was transfected into 
HEK293 cells. Cells were treated with or without MG132 (5 μM, 8hr). The same assay 
described in A was performed. C) Flag-WRN-WT or 6KR was transfected with vector, 
HA-Ub into HEK293 cells. The same assay described in A was performed. D) Flag-
WRN was transfected with vector, HA-Ub, CBP and HA-Ub, or SIRT1 and HA-Ub into 
HEK293 cells. The same assay described in A was performed. All the experiments were 
repeated at least three times. 
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2.4 Discussion 
Here, we investigated how WRN acetylation and deacetylation regulate WRN 
protein stability. First, we found that SIRT1 can interact with WRN in vitro and in vivo. 
Second, CBP and p300 are the major acetyltransferases responsible for WRN acetylation. 
Third, we identified 6 lysines as major acetylation sites of WRN protein by using mass 
spectrometry analysis and acetylation assays in cells. Fourth, we found that WRN 
acetylation can increase its protein stability. Deacetylation of WRN by SIRT1 can reverse 
this effect. CBP dramatically increases the half-life of wild type WRN, while this 
increase is abrogated with the WRN acetylation mutant. Finally, WRN stability is 
regulated by the ubiquitination pathway. WRN acetylation by CBP can dramatically 
reduce its ubiquitination, while deacetylation by SIRT1 increases its ubiquitination.  
The functions of WRN acetylation have been reported by several groups. It was 
firstly reported by Blander and colleagues that WRN acetylation is induced by DNA 
damage and is associated with translocation from nucleolus to DNA damage foci [81]. 
Vaitiekunaite and colleagues also found that SIRT1 can regulate WRN translocation 
[150]. WRN acetylation also is suggested to play an important role in regulating base 
excision DNA repair [82]. In this study, we found that acetylation can stabilize WRN 
protein through inhibiting its ubiquitination. These findings contribute significantly to our 
understanding of how WRN acetylation regulates its functions. With our complete 
identification of the WRN acetylation sites and production of acetylation mutants, more 
physiological roles of WRN acetylation will be revealed. 
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We consistently observe that WRN protein levels increase when we co-
transfected WRN with CBP/p300 compared with WRN alone. Since there is no obvious 
change in WRN mRNA levels (Fig. 2.8 A), this increased WRN level does not occur 
through transcription activation. CBP/p300 has been reported to regulate the stability of 
several proteins through acetylation; however, the precise mechanisms could be different. 
The most straightforward hypothesis is that acetylation can stabilize proteins by 
competing with ubiquitination for the same lysines. Acetylation-mediated stabilization of 
Smad7 is through competition between acetylation and ubiquitination of the same lysine 
residues [137]. A similar competitive mechanism between acetylation and ubiquitination 
was reported for SREBP1a [139], p53 [134], p73 [136], c-MYC [138] and Runx [140].  
Acetylation can stabilize proteins through other mechanisms. For instance, ER81 
acetylation sites are not ubiquitination sites. Goel et al. speculated that ER81 acetylation 
induces its conformation change, or increase interactions with other proteins to shield it 
from being recognized by ubiquitin ligases [141]. Another example is the RelA subunit of 
NF-κB. RelA methylation by methyltransferase Set9 at K314, 315 is important for its 
ubiquitination and subsequent degradation. CBP/p300 acetylates RelA at K310, and RelA 
acetylation inhibits its methylation, resulting in decreased ubiquitination and degradation. 
A model that RelA acetylation by CBP/p300 decreases the RelA and Set9 interaction has 
been proposed [148]. Our result demonstrating an increased amount of ubiquitination in 
WRN-6KR acetylation mutant (Fig. 2.9 C) supports the notion that acetylation can 
protect a protein from ubiquitination by other means than direct competition for 
modification sites.  
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In addition to CBP/P300, PCAF, another acetyltransferase, has also been reported 
to stabilize E2F1 [151] and β-Catenin [152] through acetylation. Our results show, 
however, that PCAF is unable to acetylate WRN (Fig. 2.3). 
In this study, we also examined the role of SIRT1 in the regulation of WRN 
stability. Over-expression of SIRT1 in cells decreases WRN protein levels, while down 
regulating SIRT1 by siRNA in cells can increase the WRN protein level (Fig. 2.7). 
Consistent with these findings, co-transfection of SIRT1 with WRN in cells increased the 
WRN ubiquitination level (Fig. 2.9 D), which is suspected to be responsible for WRN 
protein degradation. Our findings seem to be at odds with the results recently reported by 
Kahyo and colleagues, who found that the sirtuin-mediated deacetylation pathway 
stabilizes WRN protein. However, their assay used the SIRT1 inhibitor sirtinol for 
treating cells to detect WRN protein levels, without showing WRN acetylation and 
SIRT1-mediated WRN deacetylation [149]. Thus, it is possible that treating cells with 
Sirtinol decreased WRN protein levels through other mechanisms. Nevertheless, our 
results showing that SIRT1 down-regulates WRN protein levels are also supported by 
recent findings from Vaitiekunaite’s lab, who found that increased SIRT1 expression in 
cells was associated with down-regulation of endogenous WRN protein levels [150].  
WRN is a multi-functional protein potentially involved in many processes in 
DNA metabolism. How WRN protein is regulated in response to DNA damage remains 
largely unaddressed. Our findings that acetylation of WRN stabilizes the protein through 
inhibiting its ubiquitination advanced our understanding of WRN regulation, but the 
exact mechanism of how WRN acetylation prevents its ubiquitination remains unclear. In 
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our study, the increased amount of ubiquitination in WRN-6KR acetylation mutant 
excludes the mechanism that acetylation and ubiquitination compete for the same lysines. 
We have identified 6 lysines as WRN major acetylation sites. Further work is needed to 
identify WRN ubiquitination sites. We expect that the major ubiquitination sites of WRN 
are different from the major acetylation sites we identified. CBP decreases WRN 
ubiquitination, while SIRT1 increases WRN ubiquitination. This result is quite similar to 
the effects of CBP and SIRT on RelA ubiquitination [148]. It seems probable that 
acetylation of WRN induces a conformational change. Acetylation may decrease WRN 
interaction with other proteins which are directly important for WRN ubiquitination such 
as E3 ligases. Additionally, acetylation may affect WRN’s other PTMs which promote its 
ubiquitination as RelA protein. Acetylation may increase WRN interaction with other 
proteins, which will then mask other lysines targeting for ubiquitination and protect them 
against the activity of E3 ligases, resulting in inhibiting WRN ubiquitination. Further 
work is needed to understand the molecular details of these events.  
WRN protein is posttranslational modified by phosphorylation, acetylation, 
ubiquitination, and sumoylation. These modifications regulate WRN protein functions 
including stability, protein-protein interactions, cellular localization and enzymatic 
activities. But, it is still not clear how phosphorylation, acetylation and sumoylation 
interplay. Moreover, WRN might be regulated by other modifications such as 
ubiquitination, methylation and neddylation, which all use lysines as target. It will be 
interesting to find how these PTMs coordinate with each other in cellular processes, such 
as in response to DNA damage.  
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2.5  Materials and Methods 
Culture medium and reagents 
HEK293 and U2OS cells were obtained from American Type Culture Collection 
and cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal 
bovine serum. Anti-WRN antibody (H300) was purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). TSA, nicotinamide and anti-β-actin monoclonal 
antibody were purchased from Sigma (St. Louis, MO). Anti-acetylated-lysine antibody 
was purchased from Cell Signaling Technology (Danvers, MA). Anti-HA antibody 
(12CA5) was purchased from Roche. Anti-SIRT1antibody was made by Covance Inc. 
[98]. Transfection of the SIRT1 siRNA (Dharmacon Inc.) was performed using 
Oligofectamine reagent (Invitrogen) following the manufacturer’s instructions with a 
final oligonucleotide concentration of 20 μM.  
Co-Immunoprecipitation assay for anti-Flag M2 immunoprecipitation  
Cells were harvested 36h after transfection and were lysed in BC100 buffer (100 
mM NaCl, 50 mM Tris-HCl pH 7.3, 10% Glycerol, 0.2% Triton X-100) for 1 h. Cell 
extracts were incubated with anti-Flag M2 beads (Sigma) at 4 oC overnight. After the 
beads were washed 5 times with BC100 buffer, bound proteins were eluted with Flag 
peptide (Sigma) for 2 h. Western blots of immunoprecipitated proteins and whole cell 
extracts were performed with rabbit anti-WRN polyclonal antibody, rabbit anti-SIRT1 
polyclonal antibody, mouse anti-acetylated lysine monoclonal antibody.  
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Co-Immunoprecipitation assay for endogenous protein immunoprecipitation  
Cells were treated for 6 h with either 20 μM etoposide (Sigma) or 500 μM 
hydrogen peroxide (SM Biotech, Inc.) before harvest, then lysed with BC100 buffer for 1 
h and the cell extracts were incubated for 2 h with either goat anti-WRN polyclonal 
antibody (C19, Santa Cruz) or normal goat IgG (Santa Cruz). After incubation, Protein 
A/G PLUS agarose beads (Santa Cruz) were added to the extracts and incubated 
overnight at 4 oC. Agarose beads were washed 5 times with BC100 buffer and bound 
proteins were eluted by boiling the beads with 1x SDS sample buffer. 
GST-pulldown assay  
Full length SIRT1 protein was in vitro expressed in the presence of [35S]-
methionine by the TNT lysate in vitro translation system (Promega). GST-fusion proteins 
were expressed and purified from BL21 bacterial cells and bound to a GST-agarose 
column. [35S] radio labeled SIRT1 and GST-fusion WRN proteins were incubated for 2 h 
in buffer containing 100 mM NaCl, 20 mM Tris-HCl (pH 7.3), 10% Glycerol and 0.2 % 
Triton X-100. Beads were washed 5 times with the incubation buffer and boiled in the 
presence of 1x SDS sample buffer before SDS-PAGE. Labeled proteins were visualized 
by autoradiography.  
Detection of exogenous WRN’s acetylation in cells 
HEK293 cells were transfected using the calcium phosphate method with Flag-
WRN, and different acetyltransferase plasmid DNA (10 μg each).  At 36 h after 
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transfection, cells were lysed in Flag-lysis buffer (50 mM Tris-HCl, pH 7.8, 137 mM 
NaCl, 1 mM NaF, 1 mM NaVO3, 1% Triton X-100, 0.2% Sarkosyl, 1mM DTT, and 10% 
glycerol) containing fresh protease inhibitors, 10 μM TSA and 5 mM nicotinamide. Cell 
extracts were immunoprecipitated with anti-Flag monoclonal antibody M2 beads (Sigma). 
After elution with the Flag peptide, proteins were resolved by either 8% or 4%–20% 
SDS-PAGE (Invitrogen) and analyzed by western blot with anti-acetylated Lysine or 
anti-WRN antibodies. 
In vitro deacetylation assay 
Acetylated WRN protein was purified by co-transfecting Flag-WRN and CBP 
plasmids into HEK293 cells. Cells were treated with TSA and nicotinamide 6 h before 
harvest. Cell lysates were immunoprecipitated with anti-Flag M2 beads and eluted with 
Flag peptide. Purified acetylated WRN protein was incubated at 30oC for 1 h with 
purified SIRT1 protein as indicated. SIRT1 was Flag-tagged and purified from a stable 
cell line by immunoprecipitation with anti-Flag M2 beads and eluted with Flag peptide. 
The incubation buffer contained 50 mM Tris-HCl (pH 9), 50 mM NaCl, 4mM MgCl2, 0.5 
mM DTT, 0.2 mM PMSF, 0.02% NP-40 and 5% Glycerol. When indicated, NAD+ co-
factor (Sigma) was added to the reaction at a final concentration of 50 μM. Reaction 
mixtures were resolved in SDS-PAGE and analyzed by western Blot with monoclonal 
anti-acetylated lysine antibody. 
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Detection of endogenous WRN acetylation 
For endogenous WRN acetylation assay, cells were lysed in 1 ml RIPA buffer 
containing fresh protease inhibitors, PMSF, 10 μM TSA and 5 mM nicotinamide. The 
cell extracts were immunoprecipitated with anti-acetylated WRN specific antibody, 
incubating at 4℃ for overnight. Wash protein A/G-beads (Santa Cruz Biotechnology) 
with BC100, and add 20 μl to each tube. After wash with RIPA buffer for 3 times, add 20 
μl 2x SDS loading buffer to elute. Proteins were resolved by SDS-PAGE and analyzed by 
western blotting with anti-WRN antibodies.   
Real-time PCR 
Vector or CBP-containing plasmid DNAs were transfected into HEK293 cells. 12 
h after transfection, RNA was isolated using Rneasy (Qiagen, Valencia CA). cDNA were 
synthesized using the Superscript III enzyme (Invitrogen). Quantitative real-time PCR 
analysis was performed using SYBR green reagent (Invitrogen) on a DNA engine opticon 
2 cycler (Bio-rad laboratories, Hercules CA). The following primers were used: WRN- 
Forward, GGA TCA GCA CAG TCA GAA AAT GTT CT; WRN-Reverse, GGA TAG 
ATT CAG TTT CCT AAG TTC ACC; HPRT-Forward, ATC AGA CTG AAG AGC 
TAT TGT AAT GA; HPRT-Reverse, TGG CTT ATA TCC AAC ACT TCG TG. 
Measuring the half-life of WRN protein 
Flag-WRN alone or with CBP was transfected into HEK293 cells. 12 h after 
transfection, cells were washed with PBS, and seeded into 60-mm dishes to normalize for 
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the efficiency of the transfection. On the next day, the cells were treated with 
cycloheximide (100 μg/ ml) for indicated time. Cells were harvested and lysed in 100 μl 
RIPA buffer (10mM Tris, 150nM NaCl, 1% DOC, 0.05% SDS, 1% Triton X-100, PH 
8.0). Equal amounts of protein were separated by SDS-PAGE and analyzed by western 
blot using anti-WRN and anti-β-actin antibodies.  
Ubiquitination assay 
Flag-WRN alone or with HA-Ub was transfected into HEK293 cells. 36 h after 
transfection, cells were harvested and lysed in flag lysis buffer (50 mM Tris, 137 mM 
NaCl, 1 mM NaF, 1 mM NaVO3, 1% Triton X-100 and 0.2% Sarkosyl, 1mMDTT, 10% 
glycerol, pH 7.8) containing fresh protease inhibitors and PMSF. Cell extracts were 
immunoprecipitated with anti-flag monoclonal antibody M2 beads (Sigma). After elution 
with 20 μl 2x SDS loading buffer, proteins were resolved by SDS-PAGE and analyzed by 
western blotting with anti-HA antibody to detect ubiquitination, and anti-WRN antibody 
to detect WRN protein level.  
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CHAPTER 3: Acetylation and deacetylation of WRN protein regulates its enzymatic 
activities, cellular localization, and stability in response to DNA damage 
3.1 Abstract 
Werner syndrome (WS) is an autosomal recessive disorder associated with 
premature aging and cancer predisposition caused by mutations of the WRN gene. WS 
cells show premature senescence, increased genomic instability and are hypersensitive to 
DNA damaging drugs. WRN is a member of the RecQ DNA helicase family with 
functions in maintaining genome stability. Sir2, an NAD-dependent histone deacetylase, 
has been proven to extend life span in yeast. Human homolog SIRT1 has also been found 
to regulate premature cellular senescence induced by the tumor suppressors PML and p53. 
SIRT1 plays an important role in cell survival promoted by calorie restriction.  
We previously found that acetylation and deacetylation of WRN protein regulates 
its stability through the ubiquitin-proteasome pathway.  Here, we show that WRN 
acetylation decreases its helicase and exonuclease activities, and SIRT1 can reverse this 
effect. WRN acetylation alters its nuclear distribution. Down-regulation of SIRT1 
reduces WRN translocation from nucleoplasm to nucleolus after DNA damage is 
removed. Importantly, we found that WRN is strongly acetylated and stabilized in 
response to MMC treatment. H1299 cells stably expressing WRN-6KR, which mimics 
unacetylated WRN, display significantly higher MMC sensitivity compared with the cells 
expressing wild-type WRN. These results suggest that SIRT1 regulates WRN-mediated 
cellular responses to DNA damage through deacetylation of WRN. 
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3.2  Introduction 
Werner syndrome (WS) is a human autosomal recessive disorder that displays 
symptoms of premature aging, including graying and loss of hair, wrinkling and 
ulceration of skin, atherosclerosis, osteoporosis, and cataracts. WS patients also exhibit 
an increased incidence of diabetes mellitus type 2, hypertension, and are highly disposed 
to cancers[153]. Cells from WS patients show premature replicative senescence 
compared with cells derived from normal individuals [2]. WS cells also show 
hypersensitivity to selected DNA-damaging agents including 4NQO, topoisomerase 
inhibitors, and certain DNA cross-linking agents [3-5]. Compared to normal cells, WS 
cells also exhibit increased genomic instability including higher levels of DNA deletions, 
translocations, and chromosomal breaks [6]. 
WS results from mutation of the WRN gene, a member of the RecQ DNA helicase 
family [8] including RECQ1, BLM, WRN, RECQ4, and RECQ5. Mutation of BLM will 
cause BS [10], and Mutation of RECQ4 will cause RTS, RAPADILINO syndrome, and 
BGS [11]. Consistent with other RecQ helicases, WRN protein possesses 3' to 5' DNA 
helicase activity; however, it is the only human RecQ member to also have a 3' to 5' 
exonuclease activity. Although its physiological substrate is not yet clear, WRN appears 
to preferentially act on replication and recombination structures. 
WRN protein shows dynamic re-localization within the nucleus under different 
conditions of growth. The WRN protein localizes to the nucleolus in a variety of cell 
types [154], and this localization is modulated by DNA damage and cell cycle. Upon 
serum starvation or treatment with HU, aphidicolin, 4NQO, etoposide or CPT. WRN 
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migrates from nucleolus to discrete nuclear foci [39, 54, 73, 155-156]. The fact that DNA 
damage also induces the formation of RPA and RAD51 foci, and these co-localize with 
WRN almost fully (RPA), or partially (RAD51) [54], supports a potential role of the 
WRN protein in DNA replication and/or DNA recombination. 
Blander et al. reported that WRN is acetylated in vivo. Translocation of WRN into 
nucleoplasmic foci is significantly enhanced by the protein deacetylase inhibitor TSA. 
Moreover, TSA delays the re-localization of WRN back to the nucleolus at late times 
after DNA damage. WRN acetylation is markedly stimulated by the acetyltransferase 
p300 in vivo. Importantly, p300 augments the translocation of WRN into nucleoplasmic 
foci. These findings support the notion that WRN plays a role in the cellular response to 
DNA damage and suggest that the activity of WRN is modulated by DNA damage-
induced acetylation. Acetylation might either decrease the interaction of WRN with 
protein(s) that retain it in the nucleolus in the absence of genotoxic stress or enhance its 
interaction with proteins that anchor it to the nucleoplasmic foci [81]. Studies on WRN 
translocation after different DNA damaging treatments found that acetylation of   
endogenous   WRN   is involved in its reversible translocation from nucleolus to 
nucleoplasm [157].  
SIRT1 is the human homolog to yeast Sir2, and SIRT1 is a NAD-dependent 
histone deacetylase. SIRT1 knockout mice have a severe phenotype, most dying within 
the first month after birth [101, 158]. Consistent with regulation of p53 by SIRT1 in vivo, 
these knockout mice have hyperacetylated p53 and exhibit increased apoptosis, at least in 
thymocytes [101] and spermatogonia. More recently, Wang et al. showed that SIRT1 
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knockout mice display incomplete chromosome condensation, chromosome instability, 
and impaired heterochromatin formation, suggesting that SIRT1 plays a role in gene 
silencing. Moreover, SIRT1 deficiency causes cell-cycle abnormalities and impaired 
DNA damage repair, indicating SIRT1 may function in cell cycle regulation and DNA 
damage repair [112].   
Oberdoerffer et al. published a paper to support the role of SIRT1 in DNA 
damage repair.  In normal conditions, SIRT1 silences age-related gene expression. In 
response to DNA damage which causes DNA DSBs, SIRT1 will relocate from silence 
foci to the sites of DSBs. This relocation is dependent on ATM. SIRT1 modifies the 
chromatin near the DSBs, and recruits RAD51 and NBS1 to the DSB sites [129]. NBS1 
is a substrate for SIRT1 deacetylation [128]. These proteins function together to repair 
DSBs, resulting in increased genome stability and tumor suppression. 
Previously, we have demonstrated that acetylation and deacetylation of WRN 
protein regulates its stability through the ubiquitin-proteasome pathway.  Here, we show 
that WRN acetylation decreases its helicase and exonuclease activities, and SIRT1 can 
reverse this effect. WRN acetylation also alters its nuclear distribution and down-
regulation of SIRT1 reduces WRN translocation from the nucleoplasm to nucleolus after 
DNA damage. Importantly, we found that WRN is strongly acetylated and stabilized in 
response to MMC treatment. H1299 cells stably expressing WRN-6KR, which mimics 
unacetylated WRN, display significantly higher MMC sensitivity compared with the cells 
expressing wild-type WRN. These results suggest that SIRT1 regulates WRN-mediated 
cellular responses to DNA damage through deacetylation of WRN. 
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3.3  Results 
SIRT1 regulates both WRN helicase and exonuclease activities 
Previously, we have demonstrated that SIRT1 interacts with and deacetylates 
WRN. WRN protein is stabilized by CBP-mediated acetylation, while destabilized by 
SIRT1-mediated deacetylation. To further address the functional consequences of WRN-
SIRT1 interactions, we tested whether the WRN helicase and exonuclease activities were 
altered by these modifications. We first tested the effect of acetylation on WRN helicase 
and exonuclease activities. Using the acetylation assay described in Fig. 2.3 A, we 
expressed and purified the Flag-WRN and acetylated Flag-WRN proteins from HEK293 
cells. Using these proteins (Fig. 3.1 C, lanes 1 & 2), we performed the helicase assay on a 
21 bp partial duplex with a 49 nt 3’ overhang structure. As shown in Fig. 3.1 A, 
unacetylated WRN was consistently more efficient at unwinding this substrate than 
acetylated WRN over a range of concentration (lanes 2–4 vs. lanes 5–7).  
An exonuclease assay was also performed using the same proteins but a different 
partial duplex substrate with a recessed 3' end structure. As shown in Fig. 3.1 B, 
acetylated WRN showed markedly less exonuclease activity than unacetylated WRN 
(lanes 5–7 vs. lanes 2–4), which indicated WRN acetylation reduced WRN’s exonuclease 
activity.  
Furthermore, we tested if deacetylation of WRN by SIRT1 could reverse the 
reduction of WRN helicase and exonuclease by acetylation. For this experiment, Flag-
WRN isolated from HEK293 cells co-transfected with Flag-WRN, CBP, and SIRT1 was 
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compared with unacetylated and acetylated Flag-WRN. Using these proteins (Fig. 3.1 C, 
lane 3), we performed the helicase and exonuclease assays on the same 3' overhang and 3' 
recessed end substrates, respectively. Importantly, introduction of SIRT1 deacetylase 
(that markedly reduces the level of WRN acetylation) restores these helicase and 
exonuclease activities (Fig. 3.1 A, lanes 8–10 vs. lanes 5–7; Fig. 3.1 B, lanes 8–10 vs. 
lanes 5–7), similar to the levels attained with non-acetylated WRN. These data 
demonstrate that the acetylation state of WRN significantly affects its helicase and 
exonuclease activities, and suggest that the SIRT1 deacetylation of WRN may play an 
important role in regulation of its enzymatic function.  
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Figure 3.1 WRN enzymatic activities are regulated by acetylation and deacetylation. 
WRN and acetylated WRN proteins were obtained as described in Fig. 2.3 A and SIRT1-
deacetylated WRN proteins were obtained as described in Fig. 2.5 B. A) Helicase assay 
with 21 bp partial duplex with a 3' overhang and Flag-WRN, acetylated Flag-WRN, or 
deacetylated Flag-WRN (80, 160, and 320 pM each). Quantitative chart for WRN 
unwinding activity (mean and standard deviation for 3 independent experiments), lower 
panel B) Exonuclease assays with 35 bp partial duplex with a recessed 3' end probe and 
equal concentrations of Flag-WRN, acetylated Flag-WRN, or deacetylated Flag-WRN. C) 
Western blot for WRN proteins used in the helicase and exonuclease assays, detected by 
anti-acetylated lysine (upper panel) and anti-WRN (lower panel) antibodies. 
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DNA damage induces WRN translocation from the nucleolus to the nucleoplasm 
There is a nuclear localization signal (NLS) at WRN C terminal, and there is a 
nucleolar targeting sequence (NTS) in the RQC domain. In normal conditions, most of 
the WRN protein is in the nucleolus. Etoposide is a DNA damaging drug which will 
cause DNA Double Strand Breaks. After cells were treated with etoposide for 15 minutes, 
WRN was still in the nucleolus. After 30 minutes, WRN began to translocate from the 
nucleolus to the nucleoplasm, but some was still left in the nucleolus. After 60 minutes, 
this translocation was completed, and all WRN proteins were in the nucleoplasm. If we 
treated cells with etoposide for 1h and recovered for 24 hrs, WRN went back from the 
nucleoplasm to the nucleolus (Figure 3.2).  
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Figure 3.2 DNA damage induces WRN translocation from the nucleolus to the 
nucleoplasm. U2OS cells were untreated, or treated with etoposide for indicated time, or 
recovered for 24 hrs after etoposide treatment. Immunofluorescence staining was 
performed, using anti-WRN poly antibody to stain WRN protein and DAPI staining to 
see nucleus.  
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Blander et al. claimed that TSA, the HADC I and II inhibitor, will induce WRN to 
translocate from the nucleolus to the nucleoplasmic foci (Fig 3.3 A). They proposed that 
WRN acetylation facilitated its exit from the nucleolus [81]. We confirmed this 
conclusion. After we treated cells with etoposide for 30 minutes, most of WRN 
translocated to the nucleoplasm, but some remained in the nucleolus. TSA and 
Nicotinamide treatment significantly enhanced this translocation (Figure 3.3 B). 
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Fig. 3.3 Acetylation enhances WRN translocation in response to DNA damage. A) 
TSA induced WRN translocation from the nucleolus to the nucleoplasmic foci. B) TSA 
and nicotinamide treatment enhanced WRN translocation in response to DNA damage. 
U2OS cells were untreated, or treated with etoposide, or treated with etoposide, TSA and 
nicotinamide together. Immunofluorescence staining was performed, using anti-WRN 
poly antibody to stain WRN protein, anti-B23 to stain B23 protein as a nucleolus marker, 
and DAPI staining to see nucleus. 
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SIRT1 mediates the reentry of WRN to the nucleolus after DNA damage 
In order to test the effect of SIRT1 on WRN nuclear translocation, we first tested 
if the SIRT1 inhibitor nicotinamide can delay the reentry of WRN into the nucleolus after 
DNA damage. U2OS cells were first treated with the DNA damaging agent etoposide. 
After removing etoposide, cells were treated with nicotinamide, then fixed and 
immunostained for WRN localization. WRN underwent translocation from the nucleolus 
to the nucleoplasm after the etoposide treatment (95.8% vs. 12.5%, Fig. 3.4 B). The 
nicotinamide treatment reduced the number of cells that were able to relocate WRN back 
to the nucleolus after 24 h compared to cells without nicotinamide (85.0% vs. 51.5%, Fig. 
3.4 B). Representative cells with WRN nuclear and nucleolar localization are shown in 
Figure 3.4 A.  
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Figure 3.4 Nicotinamide delays the re-entry of WRN into nucleolus after DNA 
damage is removed. A) WRN re-localization is slowed down by the SIRT1 deacetylase 
inhibitor nicotinamide. Immunofluorescence staining of U2OS cells treated with (II) or 
without (I) 40 μM etoposide for 2 h. Etoposide was removed in two other set of cells and 
incubated with fresh medium in the presence (III) or absence (IV) of 5 mM nicotinamide 
for 24 h. B) Percentage of cells showing a positive staining for nucleolar WRN as 
represented in A. 
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We further tested whether SIRT1 was involved in regulating WRN translocation 
after DNA damage. SIRT1 protein was specifically down-regulated by siRNA to SIRT1 
in U2OS cells throughout the interval in which WRN localization was measured (Fig. 3.5 
D, lanes 2, 4, 6 vs. lanes 1, 3, 5). After etoposide treatment, both SIRT1 down-regulated 
and control cells showed similar WRN translocation to the nucleoplasm (Figs. 3.5 A and 
B). In contrast, SIRT1 down-regulated cells showed significant delay in WRN reentry 
into nucleolus compared to GFP siRNA control cells--i.e., in control cells, WRN returns 
to the nucleolus (88.6%) while it remains primarily in the nucleoplasm with much lower 
levels of nucleolar localization (23.5%) when SIRT1 levels are dramatically reduced (Fig. 
3.5 A and B). These data demonstrate that SIRT1 regulates WRN nuclear translocation in 
response to DNA damage. 
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Figure 3.5 SIRT1 knockdown delays re-entry of WRN into nucleolus after DNA 
damage is removed. A) Immunofluorescence staining of U2OS cells, which were 
transfected with SIRT1 and GFP siRNA without treatment (left panel) or treated with 40 
μM etoposide for 2h (middle panel). Another set of cells was incubated with fresh 
medium for 24h after etoposide removal (right panel). B) Percentage of cells showing 
positive staining for nucleolar WRN as represented in A. C) Immunofluorescence 
staining of U2OS cells, which were transfected with SIRT1 siRNA (upper panel) and 
GFP siRNA (lower panel). Use anti-WRN poly-antibody to stain WRN protein, and anti-
SIRT1 mono-antibody to stain SIRT1 protein. D) Down-regulation of SIRT1 by siRNA. 
U2OS cells were transfected with SIRT1 or GFP siRNA and equal amounts of total 
protein were resolved in SDS-PAGE and analyzed by western blotting with anti-SIRT1 
(upper panel) or anti-β-actin (lower panel) antibodies. Cells were analyzed without 
treatment (lanes 1 and 2), with 2 h etoposide treatment (lanes 3 and 4), with 24 h 
recovery in fresh medium after etoposide removal (lanes 5 and 6). 
  
99 
 
 
 
 
  
100 
 
SIRT1 knockdown did not induce apoptosis. 
The effect of SIRT1 on WRN re-entry was measured after 24 hrs following 1 hour 
etoposide treatment. It is possible that the re-entry interpretation can be complicated by 
the amount of detached cells, due to apoptosis. It is possible that the effect of SIRT1 is on 
apoptosis rather than re-entry into nucleolus. So, we did PI staining to the two groups 
SIRT1i and GFPi, and used flow cytometry to analyze the cell cycle. For the sub-G1 cells 
percentage, we did not see difference between these two groups. SIRT1 knockdown did 
not induce apoptosis (Figure 3.6).  
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Figure 3.6 SIRT1 knockdown did not induce apoptosis. U2OS cells were transfected 
with SIRT1 or GFP siRNA. In each group, cells were untreated, or treated with etoposide 
for 2 hrs, or recovered for 24 hrs after etoposide treatment. After PI staining, flow 
cytometry was used to measure cell cycle. The percentage of cells in sub-G1 phase 
indicating apoptosis cells was measured.  
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Temporal interaction of WRN with CBP and SIRT1 after DNA damage 
Using co-immunoprecipitation methods with anti-WRN antibody, we further 
investigated the relationship of the WRN acetylation status and the temporal interaction 
pattern of WRN, CBP and SIRT1 after DNA damage. As shown in Fig. 3.7, 30 minutes 
after etoposide treatment, the amount of WRN-associated CBP peaks, correlating with 
the time frame in which WRN acetylation markedly increases. At later time points, the 
association of WRN with CBP decreases while association with SIRT1 gradually 
increases. Taken together with our other findings, these results suggest that the early 
association of WRN with CBP followed at later times by its interaction with SIRT1 
controls the acetylation state and thus the metabolic function of WRN.   
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Figure 3.7 Temporal interaction of WRN with CBP and SIRT1 after DNA damage.  
293T cells were treated with etoposide for indicated time and the cell lysates were 
immunoprecipitated with WRN antibody. The IP products were subjected to SDS-PAGE 
and western blotted with anti CBP, WRN, and SIRT1 antibodies. 
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WRN protein is acetylated and stabilized in response to MMC 
We further investigated which DNA repair pathway WRN acetylation functions in. 
First, we examined endogenous WRN acetylation level after different DNA damage 
treatments. We treated cells with MMC, HU, etoposide, CPT, and 4NQO. After treatment, 
we used specific anti-acetylated WRN antibody to immunoprecipitate acetylated WRN 
protein. As our previous result, after etoposide treatment, endogenous WRN acetylation 
level was increased (Fig. 3.8 A lane 3). Surprisingly, after MMC treatment, endogenous 
WRN acetylation level was increased dramatically (Fig. 3.8 A lane 2). Then, we still 
treated cells with different DNA damage drugs and checked endogenous WRN protein 
level. As expected, after etoposide treatment, WRN protein level was increased (Fig. 3.8 
B lane 4). We also see that after MMC treatment, WRN protein level was increased (Fig. 
3.8 B lane 2).  
MMC is an agent that generates DNA ICLs and WS cells are hyper-sensitive to it. 
We chose MMC for further study. We treated cells with MMC for indicated time. MMC 
treatment strongly induced WRN acetylation in cells that peaked at one hour post-
treatment (Fig. 3.8 C, lane 2). As expected, WRN protein was stabilized at this same time 
point (Fig. 3.8 D, lane 2).  
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Figure 3.8 WRN protein and acetylation levels are increased after MMC treatment. 
A) HEK293 cells were not treated, or treated with MMC, etoposide, HU, CPT, and 
4NQO. Cell lysates were immunoprecipitated by anti-acetylated WRN-K1389 antibody 
and western blotted by anti-WRN antibody (upper panel). Portions of the cell lysates 
were western blotted by anti-WRN antibody to determine the equal amount of WRN 
protein in lysates for anti-acetylated WRN antibody immunoprecipitation shown in upper 
panel. B) HEK293 cells were not treated, or treated with MMC, etoposide, HU, CPT, and 
4NQO. Equal amounts of total protein were loaded on each lane and western blotted by 
anti-WRN antibody to determine the WRN amount (upper panel). Anti-β-Actin blot was 
used as loading control (lower panel). C) HEK293 cells were treated with 0.5μg/ml MMC 
for indicated time. Cell lysates were immunoprecipitated by anti-acetylated WRN-K1389 
antibody and western blotted by anti-WRN antibody (upper panel). Portions of the cell 
lysates were western blotted by anti-WRN antibody to determine the equal amount of 
WRN protein in lysates for anti-acetylated WRN antibody immunoprecipitation shown in 
upper panel. D) HEK293 cells were treated with 0.5μg/ml MMC for indicated time. 
Equal amounts of total protein were loaded on each lane and western blotted by anti-
WRN antibody to determine the WRN amount (upper panel). Anti-β-Actin blot was used 
as loading control (lower panel). 
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WRN acetylation helps cell survival in response to MMC treatment. 
To further investigate whether WRN acetylation could affect cellular response to 
MMC treatment, we generated three stable transfected cell lines. H1299 cells were 
infected with pBabe control virus or virus encoding WRN-wt or WRN-6KR containing 
lysine to arginine mutations at 6 lysine positions that mimics hypoacetylated WRN. 
WRN expression levels for the latter two cell lines are similar (Fig. 3.9 A). We also 
examined both exonuclease and helicase activities for the purified WRN-wt and WRN-
6KR mutant. The WRN-6KR mutant retains similar activities as the WRN-wt (Fig. 3.9 B 
and 3.9 C), indicating that this mutant protein folds properly and also that the 6 arginine 
substitutions do not significantly alter WRN’s catalytic activities. MTT assay was carried 
out to detect cell viability of these three WRN cell lines in response to MMC treatment. 
As shown in Fig. 3.9 D, expression of the WRN-6KR mutant that mimics hypoacetylated 
WRN resulted in a less efficient rescue of MMC treatment compared to WRN-wt. We 
also examined colony formation of the three WRN stable lines after MMC treatment. As 
shown in Fig. 3.9 E, the number of colonies from cells expressing WRN-6KR was 
significantly reduced compared to WRN-wt cells in response to the same dose of MMC. 
The vector control cells had the lowest survival rate in both assays. These results indicate 
that the WRN-6KR acetylation mutant partially impaired WRN function and suggest that 
acetylation of WRN is physiologically important for cell survival in response to MMC-
induced DNA damage.    
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Figure 3.9 WRN acetylation helps cell survival in response to MMC treatment. A) 
Cells from three virus infected stable cell lines H1299/vector (lane 1), H1299/Flag-WRN-
WT (lane 2) and H1299/Flag-WRN-6KR (lane3) were lysed and immunoprecipitated by 
anti-Flag M2 beads. WRN protein expression levels were determined by western blot 
with anti-WRN antibody. B) Equal and increasing amounts of purified WRN-wt and 
WRN-6KR mutant proteins were assayed for helicase activity on a two-stranded fork and 
the products analyzed by native PAGE as described in Methods. C) Equal amounts of 
purified WRN-wt and WRN-6KR mutant were assayed for exonuclease activity on a two-
stranded fork substrate as described in Methods and DNA products were analyzed after 
denaturing PAGE.  D) Cells from three stable cell lines were treated with increasing 
doses of MMC for 1 hr, followed by 48h recovery. MTT assays were performed. Only 
one experiment was shown here, and this experiment was repeated at least three times. E) 
Cells from three stable cell lines were treated with increasing doses of MMC for 1 hr, and 
then allowed to grow for about 2 weeks. The formed colonies were fixed in ice-cold 
methanol and stained with 0.5% crystal violet solution. The formed colonies were 
counted. Only one experiment was shown here, and this experiment was repeated at least 
three times. 
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3.4 Discussion 
We previously demonstrated that acetylation and deacetylation of WRN protein 
regulate its stability through the ubiquitin-proteasome pathway.  Here, we provide 
evidence that WRN acetylation decreases its helicase and exonuclease activities and 
SIRT1 can reverse this regulation. After treatment with the DNA damaging agent 
etoposide, WRN translocates from the nucleolus to a primarily nucleoplasmic 
localization, but returns to the nucleolus over time. Down-regulation of SIRT1 reduces 
the WRN translocation from nucleoplasm back to the nucleolus after DNA damage. 
Importantly, WRN is strongly acetylated and stabilized in response to MMC treatment. 
H1299 cells stably expressing WRN-6KR that mimics unacetylated WRN display 
significantly higher MMC sensitivity compared with the cells stably expressing wild-type 
WRN. All these data demonstrate that WRN acetylation plays significant physiological 
functions in response to DNA damage. These results are especially relevant to the cellular 
response to DNA damage, since the acetylation levels of WRN are stimulated in response 
to various types of DNA damaging agents [81], [157], and indicate an important role for 
SIRT1 in this DNA damage response. 
The dynamic re-localization within the nucleus for WRN protein is modulated by 
cell cycle and DNA damage. WRN translocates from the nucleolus to the nucleoplasm 
and DNA damage foci in responsible to various DNA damaging agents (reviewed in 
[159]) indicating that WRN participates in DNA repair at these foci. Interestingly, WRN 
acetylation has been found to coincide with this translocation  [81], [157]. Our results 
show that SIRT1 can regulate WRN localization through its interaction with and 
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deacetylation of WRN (Fig.3.4), indicating that SIRT1 is involved in the regulation of 
this and other DNA repair pathways.  
Consistent with this function, SIRT1 can deacetylate p53 and Foxo3, attenuate 
their activities and delay apoptosis after DNA damage [98], [99], [102], [103], allowing 
additional time for DNA repair processing. It is believed that the nucleolus may serve as 
a storage compartment to keep proteins from interacting with their cellular partners until 
they are required for a particular cellular response or cell-cycle stage [160]. In the 
nucleus, WRN interacts with many proteins that affect its activities in response to cellular 
stress. All these responses are time-sensitive and an overreaction of the cells to different 
insults could, instead of being beneficial, cause them irreversible damage or 
transformation. Thus, when the functional interaction is not needed for any particular 
process, WRN might be required to remain in the nucleolus until its enzymatic activities 
are needed again. Our results suggest that acetylation and SIRT1 deacetylation of WRN 
may play important roles in restricting its function by governing its cycling between the 
nucleolus and the nucleoplasm. Vaitiekunaite and colleagues reported that over-
expression of SIRT1 in cells can modulate WRN localization [150], supporting the notion 
that SIRT1 influences movement of WRN in the nucleus. A model (Fig. 4.1) based on 
our findings summarizes the regulation of WRN nuclear translocation and function by 
CBP-mediated acetylation and SIRT1-mediated deacetylation. 
WRN protein is unique among the five human RecQ members in that it contains 
both helicase and exonuclease activities. The two enzymatic activities are functionally 
and physically separable from each other. Several WRN interacting partners can 
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influence its enzymatic activities (reviewed in [161]). Post-translational modification also 
plays an important role in regulating WRN enzymatic activities. Phosphorylation of 
WRN by DNA-PKcs can inhibit its helicase and exonuclease activities and this effect can 
be reversed by Ku [63], [64]. Acetylation of WRN by p300 can mediate its translocation 
from nucleolus to nucleoplasm after DNA damage [81], [157]. Here, we show that WRN 
acetylation can also decrease its helicase and exonuclease activities on simple DNA 
substrates (Fig. 3.1). Muftuoglu and colleagues also found that acetylation of WRN 
altered its activity although their findings are somewhat different [82], perhaps due to 
different DNA substrates or assay methods. Nevertheless, the results indicate that WRN 
enzymatic activities can be regulated by acetylation in response to DNA damage. 
Interestingly, in our study, SIRT1 can interact with and deacetylate WRN and reverse the 
effects of WRN acetylation, suggesting that SIRT1 also participates in regulating WRN-
mediated DNA repair functions.  
It may be somewhat surprising that acetylation lowers WRN's basic enzymatic 
activities, considering that acetylation also is involved in recruitment of WRN to foci to 
presumably participate in a process that preserves chromosomal stability. An alternative 
scenario is that acetylation represses WRN activities until its re-localization is completed, 
when these activities are subsequently permitted by other regulatory steps such as SIRT1 
deacetylation (a possibility discussed below). It should also be mentioned that, although 
our experiments utilize assays and substrates typically used to separately monitor the 
simple unwinding and exonuclease activities of WRN, other studies suggest that the 
biochemical role of WRN may involve complex coordination of its multiple activities on 
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three- or four-stranded replication or recombination substrates, perhaps in conjunction 
with other DNA metabolic proteins. Thus, the inhibition of WRN helicase and 
exonuclease activities on simple duplexes by acetylation may not fully reflect the effect 
of this modification on WRN's actual physiological function. Additional experiments are 
planned to determine the effect of acetylation and deacetylation on WRN function in 
regard to its potential roles in replication and recombination repair. Nevertheless, it seems 
highly likely that acetylation and SIRT1 deacetylation of WRN play a key role in 
regulating both its movement in the nucleus and its biochemical function. 
Direct physical interaction between WRN and the Ku complex has been 
demonstrated by various in vitro and in vivo techniques. Ku70/80 appears to bind both 
the N-terminal and C-terminal domains of WRN [162]. Ku70 can be acetylated by CBP 
and pCAF in response to acute cell damage or stress and disrupt Ku70 from interaction 
with Bax, allowing it to localize into mitochondria and initiate apoptosis [107]. SIRT1 
interacts and deacetylates Ku70 and reverses the disruption [163]. Our finding that SIRT1 
directly interacts with and deacetylates WRN might suggest that these three proteins 
could be working in the same pathway to facilitate the DNA repair. 
WRN has been found to physically interact with p53 and the interaction involves 
C- terminal domains of both proteins [72]. The C-terminal domain of p53 also interacts 
with SIRT1 [98, 164]. Interestingly, SIRT1 also interacts with WRN C-terminal domain 
(Fig. 2.1 D, lane 3). P53 inhibits both helicase and exonuclease activities and WRN 
potentiates p53-mediated transcription [72-75]. It is possible that these three proteins 
work together to facilitate cellular DNA repair processes in damaged cells. In response to 
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DNA damage, p53 can be acetylated, activating downstream targets and inducing cell 
growth arrest, apoptosis, or senescence. SIRT1 can negatively regulate this activation by 
both deacetylating p53 and attenuating its transcriptional activity [98-100]. Here, we have 
shown that WRN acetylation reduces both its helicase and exonuclease activities and 
SIRT1 deacetylation restored these enzymatic activities (Fig. 3.1). Both p53 and WRN 
can be acetylated in response to DNA damage, and SIRT1 is involved in their subsequent 
deacetylation, probably to modulate their functions. Thus, it seems likely that these three 
proteins are involved in parallel or interrelated DNA damage response pathways in cells. 
SIRT1 deacetylation of WRN and p53 may concurrently influence the WRN DNA repair 
function while delaying or suppressing the pro-apoptotic function of p53, and therefore 
contributing to the survival of damaged cells. This is consistent with the prosurvival 
functions associated with SIRT1. In conclusion, our findings indicate that SIRT1 
regulates WRN functions following DNA damage. Further studies are necessary to 
clarify the exact role of this SIRT1 and WRN regulation in the cellular response DNA 
damage. 
Our results show that WRN is strongly acetylated and stabilized in response to 
MMC treatment. WRN acetylation seems to optimize the response to MMC treatment. 
These results demonstrate that WRN acetylation plays significant physiological functions 
in response to DNA damage. We used H1299 cells to establish the vector, WRN-wt, and 
WRN-6KR cell lines for survival assay. H1299 cells contain endogenous WRN protein 
that may affect our results. A better way is to use WRN-deficient fibroblast to establish 
these cell lines. Using these stable cell lines, we can repeat the cell survival assays in 
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response to DNA damage. Moreover, we can also use these stable cell lines to investigate 
how acetylation of WRN affects its functions in telomere maintenance and cellular 
senescence. 
In conclusion, our findings indicate that SIRT1 regulates WRN functions 
following DNA damage. Further studies are necessary to clarify the exact role of this 
SIRT1 and WRN regulation in the cellular response DNA damage.  
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3.5 Materials and Methods 
Culture medium and reagents 
HEK293, H1299 and U2OS cells were cultured in Dulbecco’s modified Eagle’s 
medium supplemented with 10% fetal bovine serum. TSA, nicotinamide and anti-β-actin 
monoclonal antibody were purchased from Sigma (St. Louis, MO). Anti-WRN antibodies 
(H300) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-SIRT1 
was made by Covance Inc. [98]. Anti-acetylated WRN specific antibody was produced 
by immunizing rabbits with a synthetic acetylated peptide (KLH-coupled) 
corresponding to residues surrounding Lys 1413 of human WRN and affinity purified 
with acetylated peptide after depletion of antibodies to unacetylated WRN by passing 
through the same peptide without acetylation of the lysine. Transfection of the SIRT1 
siRNA (Dharmacon Inc.) was performed using Oligofectamine reagent (Invitrogen) 
following the manufacturer's instructions with a final oligonucleotide concentration of 20 
μM. 
Helicase and exonuclease assay for wt, acetylated-, deacetylated-WRN protein 
Using the acetylation assay described in Figure 2.3A, we made WRN and 
acetylated WRN proteins from HEK293 cells. In order to maximally acetylate WRN 
protein, we treated the cells with TSA and nicotinamide to inhibit cellular deacetylase 
activity before harvest. Using these proteins, helicase assays were performed on a 3' 
overhang partial duplex (21 bp) DNA structure. This substrate was generated by radio 
labeling a 21-mer with [γ-32P] ATP and T4 polynucleotide kinase followed by annealing 
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with unlabeled complementary 70-mer. Non-acetylated, acetylated, and deacetylated 
Flag-WRN proteins were incubated with substrate for 5 min at 37°C in WRN reaction 
buffer (40 mM Tris–HCl, pH 8.0, 4 mM MgCl2, 1 mM ATP, 0.1% NP-40, 0.1 mg/ml 
bovine serum albumin [BSA], and 5 mM DTT). Reactions were stopped by addition of 
one-sixth volume of loading dyes (30% glycerol, 0.25% bromophenol blue, 0.25% xylene 
cyanol, 50 mM EDTA, and 0.9% SDS). Samples were subjected to electrophoresis in an 
8% neutral gel in 1x TBE at 100 V for 3 h at room temperature. The gel was vacuum 
dried at 80°C for 1 h and radioactive DNA was visualized by phosphor imaging. For the 
exonuclease assay, a partial duplex (35 bp) with a recessed 3' end was constructed by 
annealing labeled 35-mer to a twofold excess of unlabeled 70-mer, separated by native 
PAGE (12%), excised and extracted before use.  Exonuclease reactions (10 μl) containing 
3' recessed end substrate (0.1 nM) and Flag-WRN proteins at the indicated concentrations 
in WRN reaction buffer minus ATP were pre-incubated on ice for 5 min then transferred 
to 37°C for 5 min.  Reactions were stopped by addition of formamide loading buffer (95% 
formamide, 20 mM EDTA, 0.1 % bromophenol blue and 0.1% xylene cyanol). DNA 
products were heated at 95°C and separated by denaturing (14%) PAGE. Digestion of the 
labeled strand by the 3' to 5' exonuclease activity of WRN proteins was visualized by 
phosphor imaging. 
Immunofluorescence and recovery assays 
 U2OS cells were seeded onto duplicated sterile cover slips in a 6-well tissue-
culture plate at 20–30% confluence. Cells were treated with 40 μM etoposide for 2 h and 
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then washed and supplied with fresh medium for an additional 24 h. Nicotinamide (5 mM) 
was used as indicated in specific wells. For the SIRT1 down-regulation experiment, cells 
were transfected with siRNA for SIRT1 (or in control experiments, siRNA for GFP) by 
Oligofectamine reagent (Invitrogen) following manufacturer instructions with a final 
concentration of the siRNA oligonucleotides of 20 μM. The siRNA sequences for SIRT1: 
AACTTGTACGACGAAGACGAC. The cells were treated with etoposide as above. At 
each time point, cells were fixed in PBS containing 4% paraformaldehyde for 20 minutes 
and permeabilized with PBS containing 1% of BSA and 0.1% Triton X-100 for 5 minutes. 
Primary mouse anti-WRN monoclonal antibody (BD Biosciences Pharmingen) was 
added in 1% BSA/PBS for 45 min at room temperature. After washing with 1% 
BSA/PBS, FITC-conjugated anti-mouse antibody (1:400; Jackson ImmunoResearch 
Laboratories) was added and incubated for 30 min at room temperature. Finally, cells 
were counterstained with DAPI to visualize the nuclei. Coverslips were mounted in Aqua 
Poly/Mount (Polysciences). And the slides were examined under an Olympus IX71 
microscope. 
Helicase and exonuclease assay for WRN wt and mutant protein 
Helicase assays were performed on a two-stranded fork substrate containing a 31 
and 21 nt 5’ and 3’ single-stranded arms, respectively. This substrate was generated by 
radio labeling a 62-mer (5’-
CACTGACTCCAGGAACTGGAGGATGCCTAGGTGGCCAGCTGCCGTCCAG-
ACTCAGAGGAGTG-3’) with [γ-32P]-ATP and T4 polynucleotide kinase followed by 
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annealing with unlabeled, partially complementary 52-mer (5’-
CACTCCTCTGAGTCTGGACGGCAGCT- 
GGCCAAGTGTGAGTGTGAGTGTGAGT-3’). Annealed substrate was gel-purified and 
eluted into 10 mM Tris pH 8.0, 10 mM NaCl. Flag-tagged WRN-wt and WRN-6KR 
proteins were incubated with substrate for 30 min at 37˚C in 20 μl of WRN reaction 
buffer (40 mM Tris-HCl, pH 8.0, 1 mM MgCl2, 250 μM ATP, 0.1% NP-40, 100 μg/ml 
BSA, and 5 mM DTT). Reactions were subsequently incubated with Proteinase K (1 
mg/ml), SDS (0.2%) and EDTA (5 mM) for 30 min at 37˚C and then stopped by addition 
of one-sixth volume of loading dyes (30% glycerol, 0.25% bromphenol blue, 0.25% 
xylene cyanol, and 50 mM EDTA). Samples were subjected to native polyacrylamide 
(6%) gel electrophoresis (PAGE) in 1X TBE buffer at 100 V for 3 h at room temperature. 
Gels were vacuum-dried and radioactive DNA was visualized by phosphor imaging. The 
WRN exonuclease assay utilized a similar two-stranded fork substrate (containing 31 and 
21 nt 5’ and 3’ single-stranded arms, respectively), constructed by annealing the labeled 
62-mer (as above) to an unlabeled 52-mer (5’-TCACTTGACAAGTGACTGTGAC- 
CTAGGCATCCTCCAGTTCCTGGAGTCAGTG-3’) then purified as above. WRN-wt 
and WRN-6KR proteins were preincubated on ice for 5 min in 10 μl of WRN reaction 
buffer (including 1 mM MnCl2 instead of MgCl2), and then transferred to 37˚C for 20 
min. Reactions were stopped by addition of formamide loading buffer (95% formamide, 
20mM EDTA, 0.1% bromophenol blue, and 0.1% xylene cyanol), heated at 90˚C and the 
DNA products separated by denaturing (8%) PAGE. After gel drying, digestion of the 
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labeled strand by the 3’ to 5’ exonuclease activity of WRN proteins was visualized by 
phosphor imaging. 
MTT assay 
Cells were seeded in 96-well plates, allowed to attach overnight, then treated with 
increasing doses of MMC (0.1, 0.5, 1.0 μg/ml) for 1 h and then incubated for another 48 
h. Aliquots of 10 μl of MTT (5 mg/ml) were added to each well. After 4 h, the color 
formed was quantified by a spectrophotometric plate reader (Berkman, Inc) at 595 nm 
wavelength after solubilization in 100 μl of DMSO.  
Colony formation assay 
Cells (1000 per 6cm dish) were plated in triplicate. After overnight attachment, 
cells were treated with three different concentrations of MMC (0.1, 0.5, 1.0 μg/ml) for 1 
h and then allowed to grow for about 2 weeks. The formed colonies were fixed in ice-
cold methanol and stained with 0.5% crystal violet solution. The formed colonies were 
counted.  
Detection of endogenous WRN acetylation 
For endogenous WRN acetylation assay, cells were lysed in 1 ml RIPA buffer 
containing fresh protease inhibitors, PMSF, 10 μM TSA and 5 mM nicotinamide. The 
cell extracts were immunoprecipitated with anti-acetylated WRN specific antibody, 
incubating at 4℃ for overnight. Wash protein A/G-beads (Santa Cruz Biotechnology) 
with BC100, and add 20 μl to each tube. After wash with RIPA buffer for 3 times, add 20 
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μl 2x SDS loading buffer to elute. Proteins were resolved by SDS-PAGE and analyzed by 
western blotting with anti-WRN antibodies.   
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CHAPTER 4: Conclusions and future perspectives 
WRN is a multifunctional protein in DNA metabolism, including DNA 
replication, recombination, and repair. The fact that WRN interacts physically and 
functionally with many important proteins involving in regulation of DNA metabolism 
provides major evidence to support this notion. However, the precise role of WRN in 
DNA repair is still unclear. The common sense in the field at this stage is that WRN may 
facilitate DNA repair through different pathways, such as HR, NHEJ, and BER. Although 
WRN can be modified by different posttranslational modifications, how these 
modifications regulate WRN protein functions in response to DNA damage remains a 
high interested subject. We have confirmed the original finding by Blander et al. that 
acetylation of WRN enhances its translocation from the nucleolus to the nucleoplasm in 
response to DNA damage. We further found that SIRT1 interacts with and deacetylates 
WRN.  Deacetylation of WRN by SIRT1 also regulates its cellular localization in 
response to DNA damage. SIRT1 helps WRN translocating back to the nucleolus from 
the nucleoplasm after DNA damage, and this process is inhibited by nicotinamide 
treatment or SIRT1 down-regulation.  
Besides cellular localization, we also demonstrated that WRN acetylation and 
deacetylation by SIRT1 regulate its stability. First, we found that CBP and p300 are the 
major acetyltransferases for WRN acetylation and we identified 6 lysine residues as 
major acetylation sites for WRN protein. Second, acetylation of WRN by CBP increases 
WRN’s stability through inhibiting the ubiquitin-proteasome pathway. Conversely, 
deacetylation of WRN by SIRT1 decreases its stability.  
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WRN contains 3’–5’ helicase activity and 3’–5’ exonuclease activity. These 
enzymatic activities play indispensible roles for WRN functions. We demonstrated that 
acetylation of WRN inhibits both helicase and exonuclease activities, while deacetylation 
by SIRT1 reverses this inhibition. The functional consequences of this regulation remain 
unresolved. The possible role could be facilitating the translocation of WRN protein from 
nucleolus to DNA damage foci. The inhibition could prevent undesired damage caused 
by these enzymatic activities. Once the WRN protein reached the damage foci, SIRT1 
deacetylation recover the enzymatic activities for optimal repair. In current stage, we only 
tested simple substrates for this experiment, we will further examine more substrates in 
physiological condition in the future study.  
Importantly, we found that WRN protein is strongly acetylated and stabilized in 
response to mitomycin C (MMC) treatment. We have established stable cell lines which 
express WRN wt protein or acetylation mutant protein. Cells stably expressing WRN 
acetylation mutant display significantly higher sensitivity to MMC than the cells 
expressing wild-type WRN. One reason is that the regulation of WRN by acetylation and 
deacetylation is destroyed in the cells that express WRN acetylation mutant.    
Based on this study, we have proposed a model (Fig. 4.1) that addresses the 
regulation of WRN by acetylation and SIRT1-mediated deacetylation in response to 
DNA damage. The future perspective for this project will be more focused on the study 
of the regulation of WRN acetylation and SIRT1 mediated deacetylation in more 
physiological condition, such as to examine the role of WRN-SIRT1 interaction in 
telomere function and to test the role of WRN acetylation and deacetylation pathway in 
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cellular senescence. Such research will help us to understand the precise roles of both 
WRN and SIRT1 in physiological condition and will provide new insights into the 
regulation of WRN protein.  
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Figure 4.1 A model for regulation of WRN function by acetylation and SIRT1- 
mediated deacetylation in response to DNA damage. 
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WRN and its homologs  
There are WRN homologs in many other species from bacteria to mammals. The 
WRN gene is conserved in chimpanzee, dog, mouse, chicken, zebrafish, and C. elegans. 
FFA-1 is the homologue of WRN in Xenopus. SGS1 and Rqh1 are the homologues of 
WRN in S. cerevisiae, and S. pombe, respectively.  RecQ is the homologue of WRN in E. 
coli. Human WRN is a 1432 AA protein. Using mass-spectrometry and in vivo 
acetylation assay, we have identified 6 lysines as major acetylation sites of WRN: Lysine 
366, 887, 1117, 1127, 1389, and 1413. We want to check if these identified lysines are 
conserved in the homologues of WRN in other species. If a lysine is conserved during 
evolution, this indicates that particular lysine might be essential for the acetylation of 
WRN protein. 
All of these 6 lysines are conserved in chimpanzee. Five lysines except K1389 are 
conserved in dog. Only the K887 is conserved in chicken and S. cerevisiae, and only the 
k366 is conserved in Xenopus. None of these 6 lysines is conserved in lower species, 
such as Zebrafish, C. elegans, and E. coli.  
Mouse WRN contains 1401 AA. Lysine 887, 1117, 1127, 1389, and 1413 are 
conserved both in human and mouse, but not the Lysine 366. The major difference 
between the human WRN protein and the mouse WRN protein is their cellular 
localizations. In normal conditions, most of the human WRN protein localizes in the 
nucleolus, while mouse WRN protein is distributed throughout the nucleus. The reason 
for the difference is that human WRN protein contains a NTS (nucleolar targeting 
sequence) at its C-terminus, while mouse WRN protein does not. Many groups have 
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established WRN knockout mouse, and only the WRN Terc double-knockout mice 
display WS-like phenotypes. 
The DNA repair pathway(s) in which WRN acetylation and deacetylation function 
Although we have studied WRN acetylation and deacetylation by SIRT1 in 
response to DNA damage, we are still not sure about the DNA repair pathway(s) in which 
this regulation functions. In order to define this, we have treated cells with different DNA 
damaging drugs. We found that the WRN acetylation level increased only after etoposide 
or MMC treatment. Etoposide is an inhibitor of topoisomerase II, and will induce DNA 
DSBs. There are two pathways to repair DNA DSBs: HR and NHEJ.  WRN may function 
in both pathways because WRN interacts with proteins involved in both pathways. 
However, the specific role of WRN is still under investigation. In the NHEJ pathway, 
WRN might process the DNA ends with its exonuclease activity before X4L4 complexes 
are able to ligate them together. It might be that WRN acetylation and deacetylation 
maybe regulates its function in this process. We demonstrated that acetylation of WRN 
inhibits its exonuclease activity and that deacetylation by SIRT1 reverses this inhibition. 
It is possible that, at the early stages, WRN is deacetylated by SIRT1 to increase its 
exonuclease activity to process the DNA ends. At the latter stages, CBP/p300 also 
translocates to DNA DSBs sites and binds to WRN and acetylates WRN. WRN 
acetylation inhibits its ability to chop DNA ends in order to prevent extensive deletion. 
BLM together with TOPOIIIα and the RMI1-RMI2 complex resolve the HJ in the late 
step of the HR pathway [9]. WRN may also functions in the dissolution of the HJ using 
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its helicase activity. Deacetylation of WRN by SIRT1 might increase its helicase activity 
to facilitate the dissolution. We will use homologous recombination assay, which has 
been described by Litman et al. [165], to test if the HR pathway is impaired in the cells 
which stably express WRN acetylation mutant protein.  
In our experiment, WRN acetylation is significantly increased after MMC 
treatment. MMC treatment induces DNA ICLs, which require both NER and HR 
pathways to repair. WS cells are hypersensitive to drugs that induce DNA ICLs [5], 
indicating that WRN functions in ICLs repair. It has been reported that WRN and 
BRCA1 function together in response to DNA ICLs, and processing of DNA ICLs 
requires the helicase activity of WRN [52]. But, the specific role of WRN in ICLs repair 
is still not clear. WRN can help to restart the stalled replication forks, which has been 
discussed in the introduction with regard to the function of WRN in DNA replication. It 
is very likely that WRN will also promote fork regression in the DNA ICLs repair, to 
prepare a substrate for the following Mus81–Eme1 cleavage. WRN can coordinate its 
helicase activity and ss DNA-annealing activity to regress a model replication fork 
structure. Having demonstrated that acetylation and deacetylation by SIRT1 regulate 
WRN helicase activity on simple DNA structure, we will use the model replication fork 
structure for further study. It is tempting to speculate that acetylation and deacetylation of 
WRN also regulate its ss DNA-annealing activity.  
WRN functions in the BER pathway, which has been supported by WRN’s 
interactions with many other proteins involved in BER. WRN stimulates pol β strand 
displacement DNA synthesis, depending on its helicase activity. This function of WRN is 
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regulated by acetylation. WRN acetylation stimulates strand displacement synthesis by 
pol β more strongly than unacetylated WRN, resulting in increased long-patch BER 
synthesis. WRN acetylation is increased after MMS treatment. It is very possible that 
SIRT1 can deacetylate WRN in this process, and that deacetylation of WRN by SIRT1 
also regulates its ability to stimulate strand displacement synthesis by pol β.  
The signal transduction from the DNA damage sites to the WRN protein 
In normal conditions, most of WRN protein localizes in the nucleolus. It will be 
interesting to study how the signal is transmitted from the DNA damage sites to the WRN 
protein. ATM is activated by DNA DSBs. ATM can phosphorylate many downstream 
proteins, including WRN. Phosphorylation of WRN can enhance its translocation from 
the nucleolus to the nucleoplasm. It has also been reported that WRN is required for 
ATM to activate the S phase checkpoint in response to ICL-induced DSBs [80], thus 
forming a positive feedback loop. Other than DNA DSBs, different DNA damages can 
activate different kinases such as ATR and DNA-PKcs. WRN protein has been reported 
to be a substrate for ATR and DNA-PKcs. Phosphorylation by ATR or DNA-PKcs may 
also help WRN translocation from the nucleolus to the DNA damage sites in response to 
these types of DNA damages. 
Besides phosphorylation, acetylation might also help signal transduction from the 
DNA damage sites to the nucleolar WRN protein.  We have identified CBP/p300 as the 
major acetyltransferases for WRN. After DNA damage, CBP/p300 will acetylate WRN, 
as they acetylate p53. Acetylation of p53 will induce apoptosis in response to DNA 
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damage. It has been demonstrated by other groups and by us that acetylation can enhance 
WRN translocation from the nucleolus to the nucleoplasm in response to DNA damage. 
But the mechanism remains unknown. WRN acetylation may increase its interaction with 
the nucleoplasmic proteins, or it may decrease its interaction with nucleolar proteins. 
Further studies are needed to identify these proteins.  
WRN acetylation and deacetylation by SIRT1 pathway in telomere maintenance 
As discussed in the introduction, WRN functions in telomere maintenance. Only 
the WRN and Terc double-knockout mice display the same phenotypes as the WS 
patients. Crabbe et al. found that the replication of telomeres by lagging-strand synthesis 
is compromised in WRN-deficient cells, and that WRN helicase activity is required for 
the replication of telomere lagging strand.WRN interact physically and functionally with 
telomeric proteins including TRF1, TRF2, and POT1. Telomeric structures such as G-
quadruplexes and D-loops are preferred substrates for WRN helicase and exonuclease 
activities. Cells that are lack of WRN exhibit deletion of telomeres from single-sister 
chromatids. Yeast Sir2 functions in the telomere silencing along with Sir3 and Sir4.  
Although there is no direct evidence that SIRT1 plays a role in telomere, based on our 
preceding work, it is very likely that SIRT1 functions in telomere through deacetylating 
WRN.  
To investigate possible WRN-SIRT1 interaction in telomere function, we will 
first examine the WRN acetylation status in telomere and test the acetylated WRN 
telomere localization after drug treatment. We expect that WRN acetylation may regulate 
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WRN translocation into telomere and that acetylation may increase the interaction of 
WRN and TRF2 in telomere. Second, we will examine the co-localization of SIRT1 and 
WRN at the telomere before and after drug treatment. We expect that WRN and SIRT1 
will also increase the interaction in telomere for WRN deacetylation. Third, we will also 
test whether or not the WRN acetylation and deacetylation by SIRT1 play a role in its 
ability to dissociate the telomeric D loop. The in vitro helicase assay will be performed 
by using telomeric D loop probe [21] and acetylated WRN and SIRT1 deacetylated WRN 
proteins. The WRN acetylation mutants WRN-6KR and WRN-6KQ proteins will also be 
used to test the telomeric D loop dissociation. Since acetylation of WRN reduces its 
helicase activity, we expect that acetylation of WRN will also reduce its helicase activity 
at telomeric D loop probe. 
Lastly, because WRN is required for the replication of telomere lagging strand, 
we will test if WRN acetylation and deacetylation by SIRT1 affect this process. At the 
first step, we will use SV40-transformed WS fibroblasts to establish WRN wt and 6kr 
stable cell lines, as follows: Both WRN wt and 6kr will be first introduced into retroviral 
expression pBabe vector and the pseudotyped viruses were produced. The WS fibroblasts 
will be infected with different viruses and selected by puromycin. Then, we will use 
Fluorescent in situ hybridization (FISH) of metaphase telomeres prepared from these 
cells to test the effect of WRN acetylation on telomere replication. Next, we will use 
siRNA to knock down endogenous SIRT1 in WRN wt stable cells, to test if WRN 
deacetylation by SIRT1 will affect telomere replication. We expect that the WRN-6KR 
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mutant may exhibit increased events of sister telomere loss because the WRN-6KR 
mutant may lose the regulation of translocation of WRN protein into telomere. 
WRN acetylation and deacetylation pathway in cellular senescence 
WS patients display premature aging. WS cells have reduced life span and 
undergo premature replicative senescence much faster than do normal cells.  An extra 
copy of Sir2 gene can increase yeast life span, while deletion of Sir2 shortens life span. 
Sir2 homologs also increase life span in other organisms, and SIRT1 expression is 
increased in CR mice. SIRT1 can also regulate premature cellular senescence induced by 
PML and p53 [100]. Both WRN and SIRT1 are involved in the regulation of cellular 
senescence, together with our preceding work, it is very possible that WRN and SIRT1 
may work together to regulate cellular senescence.  
To test this hypothesis, we will first use the vector, WRN-wt, WRN-6kr stable 
cell lines, as described above. The cells will be cultured for about 20 population doubling 
time for senescence assays to evaluate the senescence phenotype, and these assays 
include growth curve analysis, BrdU incorporation, cell-cycle analysis, and SA-β-gal 
assay. Second, we will investigate the possibility that WRN and SIRT1 may work 
together in cellular senescence. We will introduce SIRT1 protein into the WS fibroblasts 
that are stably expressing WRN-wt, and the similar senescence assays will be performed. 
Conversely, we can use siRNA to knock down the endogenous SIRT1 protein in the WS 
fibroblasts that are stably expressing WRN-wt, and then we can perform the senescence 
assays. 
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SIRT1 as therapeutic target 
SIRT1 has been set as therapeutic target for many age-related diseases, including 
tumor, diabetes, cardiovascular diseases, neurodegenerative diseases, and inflammatory 
diseases. SIRT1 is regulated by many other proteins and small molecules. SIRT1 
activators and inhibitors have been developed into drugs to treat diseases. For example, 
resveratrol, a SIRT1 activator, has been shown to prevent skin tumors [166], colon cancer 
[167], and prostate cancer [168] in mice. Drinking red wine is believed to be able to 
improve human health, and resveratrol is a component of red wine.  
Identifying SIRT1 downstream targets is also very important. SIRT1 can 
deacetylate p53, and identifying the SIRT1-P53 pathway greatly helps us understand the 
roles of these two proteins in tumorigenesis. Here, we identify WRN protein as another 
downstream target, and demonstrate WRN-SIRT1 pathway in DNA damage response.  
Moreover, WRN-SIRT1 pathway may also function in telomere maintenance and cellular 
senescence. WS patients display premature aging and develop many age-related diseases. 
WS cells are hypersensitive to numerous DNA-damage agents and show increase 
genomic instability. One reason for these phenotypes might be the deregulation of the 
WRN-SIRT1 pathway in WS patients. SIRT1-activator or inhibitor drugs may take effect 
through regulating the WRN-SIRT1 pathway in these cellular processes.  
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